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A B S T R A C T
Background
Otitis media with effusion (OME) is characterised by an accumulation of fluid in the middle ear behind an intact tympanic membrane,
without the symptoms or signs of acute infection. Since most cases of OME will resolve spontaneously, only children with persistent
middle ear effusion and associated hearing loss potentially require treatment. PreviousCochrane reviews have focused on the effectiveness
of ventilation tube insertion, adenoidectomy, nasal autoinflation, antihistamines, decongestants and corticosteroids in OME. This
review, focusing on the effectiveness of antibiotics in children with OME, is an update of a Cochrane review published in 2012.
Objectives
To assess the benefits and harms of oral antibiotics in children up to 18 years with OME.
Search methods
The Cochrane ENT Information Specialist searched the ENT Trials Register; Central Register of Controlled Trials (CENTRAL 2016,
Issue 3); PubMed; Ovid EMBASE; CINAHL; Web of Science; ClinicalTrials.gov; ICTRP and additional sources for published and
unpublished trials. The date of the search was 14 April 2016.
Selection criteria
Randomised controlled trials comparing oral antibiotics with placebo, no treatment or therapy of unproven effectiveness in children
with OME.
Data collection and analysis
We used the standard methodological procedures expected by Cochrane.
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Main results
Twenty-five trials (3663 children) were eligible for inclusion. Two trials did not report on any of the outcomes of interest, leaving
23 trials (3258 children) covering a range of antibiotics, participants, outcome measures and time points for evaluation. Overall, we
assessed most studies as being at low to moderate risk of bias.
We found moderate quality evidence (six trials including 484 children) that children treated with oral antibiotics are more likely to
have complete resolution at two to three months post-randomisation (primary outcome) than those allocated to the control treatment
(risk ratio (RR) 2.00, 95% confidence interval (CI) 1.58 to 2.53; number needed to treat to benefit (NNTB) 5). However, there is
evidence (albeit of low quality; five trials, 742 children) indicating that children treated with oral antibiotics are more likely to experience
diarrhoea, vomiting or skin rash (primary outcome) than those allocated to control treatment (RR 2.15, 95% CI 1.29 to 3.60; number
needed to treat to harm (NNTH) 20).
In respect of the secondary outcome of complete resolution at any time point, we found low to moderate quality evidence from five
meta-analyses, including between two and 14 trials, of a beneficial effect of antibiotics, with a NNTB ranging from 3 to 7. Time periods
ranged from 10 to 14 days to six months.
In terms of other secondary outcomes, only two trials (849 children) reported on hearing levels at two to four weeks and found
conflicting results. None of the trials reported data on speech, language and cognitive development or quality of life. Low quality
evidence did not show that oral antibiotics were associated with a decrease in the rate of ventilation tube insertion (two trials, 121
children) or in tympanic membrane sequelae (one trial, 103 children), while low quality evidence indicated that children treated with
antibiotics were less likely to have acute otitis media episodes within four to eight weeks (five trials, 1086 children; NNTB 18) and
within six months post-randomisation (two trials, 199 children; NNTB 5). It should, however, be noted that the beneficial effect of
oral antibiotics on acute otitis media episodes within four to eight weeks was no longer significant when we excluded studies with high
risk of bias.
Authors’ conclusions
This review presents evidence of both benefits and harms associated with the use of oral antibiotics to treat children up to 16 years
with OME. Although evidence indicates that oral antibiotics are associated with an increased chance of complete resolution of OME
at various time points, we also found evidence that these children are more likely to experience diarrhoea, vomiting or skin rash. The
impact of antibiotics on short-term hearing is uncertain and low quality evidence did not show that oral antibiotics were associated
with fewer ventilation tube insertions. Furthermore, we found no data on the impact of antibiotics on other important outcomes such
as speech, language and cognitive development or quality of life.
Even in situations where clear and relevant benefits of oral antibiotics have been demonstrated, these must always be carefully balanced
against adverse effects and the emergence of bacterial resistance. This has specifically been linked to the widespread use of antibiotics
for common conditions such as otitis media.
P L A I N L A N G U A G E S U M M A R Y
Antibiotics for otitis media with effusion (’glue ear’) in children
Review question
This review compared the effects of oral antibiotics against placebo, no treatment or other therapies in children with otitis media with
effusion (OME) or ’glue ear’.
Background
Glue ear is one of the most common conditions of early childhood. Glue ear means that there is fluid in the middle ear space behind
the eardrum. This may cause hearing difficulties that may in turn affect children’s behaviour, language and progress at school. In
approximately one in three children with glue ear, bacteria are identified in the middle ear fluid. Therefore, people have suggested that
antibiotics may be beneficial in children with glue ear.
Study characteristics
This review included evidence available up to 14 April 2016. In total 25 studies (3663 children) were eligible for inclusion. Two studies
did not report on any of the outcomes of interest, leaving 23 studies (3258 children). Overall, we assessed most studies as being at low
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to moderate risk of bias. In the 23 studies many different antibiotics were used and the children were of different ages and had suffered
from glue ear for various lengths of time. They looked at the benefits at various time points after the treatment was given.
Key results
The most important outcomes that we measured were the difference in the proportion of children who no longer had glue ear two to
three months after the treatment was started and adverse effects of antibiotics (diarrhoea, vomiting or skin rash).
We found moderate quality evidence (six trials including 484 children) that children treated with oral antibiotics are more likely to
have glue ear resolved two to three months after the treatment was started than those allocated to control treatment. The number of
children needed to treat for one beneficial outcome (NNTB) was five. However, there is evidence (albeit of low quality; five trials, 742
children) indicating that children treated with oral antibiotics are more likely to experience diarrhoea, vomiting or skin rash than those
allocated to control treatment. The number of children needed to treat for one harmful outcome (NNTH) was 20.
In respect of the secondary outcome of having glue ear resolved at any time point, we found low to moderate quality evidence from
five of our analyses where we combined data from studies (meta-analyses), which included between two and 14 studies, of a beneficial
effect of antibiotics, with a NNTB ranging from three to seven. Time periods ranged from 10 to 14 days to six months.
In terms of other secondary outcomes, only two trials (849 children) reported on hearing levels at two to four weeks and found
conflicting results. None of the trials reported data on speech, language and cognitive development or quality of life. Low quality
evidence did not show that oral antibiotics were associated with fewer ventilation tube (grommet) insertions (two trials, 121 children) or
in adverse consequences for the tympanic membrane (ear drum) (one trial, 103 children). Low quality evidence indicated that children
treated with oral antibiotics were less likely to have acute otitis media (ear infection) episodes within four to eight weeks (five trials,
1086 children; NNTB 18) and within six months after treatment was started (two trials, 199 children; NNTB 5). It should however
be noted that the beneficial effect of oral antibiotics on ear infection episodes within four to eight weeks was no longer significant when
studies with high risk of bias were excluded.
Quality of the evidence
Moderate quality evidence is available that children with glue ear do benefit from oral antibiotics in terms of resolving glue ear at
various time points and reducing acute otitis media episodes during follow-up compared with control treatment. Low quality evidence
is available that children treated with oral antibiotics are more likely to experience diarrhoea, vomiting and skin rash than those receiving
the control treatment. Currently only two trials have assessed the impact of oral antibiotics on hearing and these showed conflicting
results (low quality evidence). Low quality evidence did not show that oral antibiotics were associated with fewer ventilation tube
insertions or in adverse consequences for the tympanic membrane.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Antibiotics compared to placebo, no treatment or therapy of unproven effectiveness for otitis media with effusion in children
Patient or population: children with ot it is media with ef fusion
Setting: community, primary care, secondary care and tert iary care
Intervention: ant ibiot ics
Comparison: placebo, no treatment or therapy of unproven ef fect iveness
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with control treat-
ment
Risk with antibiotics
Complete resolut ion of
OME at 2 to 3 months
Study populat ion RR 2.00
(1.58 to 2.53)
484
(6 RCTs)
⊕⊕⊕©
moderate 1
The NNTB based on the
study populat ion risk
was 1/ (493-247)* 1000
= 4.07
247 per 1000 493 per 1000
(390 to 624)
Adverse ef fects Study populat ion RR 2.15
(1.29 to 3.60)
742
(5 RCTs)
⊕⊕©©
low 2
The NNTH based on the
study populat ion risk
was 1/ (97-45)* 1000 =
19.23
45 per 1000 97 per 1000
(54 to 149)
Complete resolut ion of
OME at 2 to 4 weeks
Study populat ion RR 1.98
(1.47 to 2.67)
2091
(14 RCTs)
⊕⊕©©
low2
The NNTB based on the
study populat ion risk
was 1/ (403-203)* 1000
= 5.00
203 per 1000 403 per 1000
(299 to 543)
Complete resolut ion of
OME at more than 6
months
Study populat ion RR 1.75
(1.41 to 2.18)
606
(5 RCTs)
⊕⊕©©
low 2
The NNTB based on the
study populat ion risk
was 1/ (445-255)* 1000
= 5.26
255 per 1000 445 per 1000
(359 to 555)
Insert ion of vent ilat ion
tubes
Study populat ion RR 0.90
(0.46 to 1.78)
121
(2 RCTs)
⊕⊕©©
low 3
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185 per 1000 167 per 1000
(85 to 330)
Tympanic membrane
sequelae
Study populat ion RR 0.42
(0.18 to 1.01)
103
(1 RCT)
⊕⊕©©
low 4
-
275 per 1000 115 per 1000
(49 to 277)
* The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95% CI).
CI: conf idence interval; NNTB: number needed to treat to benef it ; NNTH: number needed to treat to harm; OM E: ot it is media with ef fusion; RCT: randomised controlled trial;
RR: risk rat io
GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
M oderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1We downgraded the evidence f rom high to moderate quality due to study lim itat ions (risk of bias).
2We downgraded the evidence f rom high to low quality due to study lim itat ions (risk of bias) and inconsistency of ef fect
est imates across individual trials.
3We downgraded the evidence f rom high to low quality due to study lim itat ions (risk of bias) and imprecise ef fect est imates
across individual trials.
4We downgraded the evidence f rom high to low quality due to concerns around directness of evidence: one trial included
part icipants part icularly at risk for suppurat ive ot it is media (Australian Aboriginal children in rural Australia) and had a lim ited
number of children, leading to an imprecise ef fect est imate.
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B A C K G R O U N D
Description of the condition
Symptoms, prevalence and aetiology
Otitis media with effusion (OME) or ’glue ear’ is one of the most
common diseases of early childhood. OME is characterised by an
accumulation of fluid in themiddle ear behind an intact tympanic
membrane, without the symptoms or signs of acute infection (
Gates 2002; Shekelle 2002).
The potential absence of symptoms of OME makes it difficult to
estimate its true prevalence, but in the first year of life more than
50% of children will experience an episode of OME, increasing
to more than 60% by two years of age (Casselbrant 2003).
When OME is newly detected, natural resolution (i.e. disappear-
ance of the fluid from the middle ear space) within three months
is seen in 28% of children. Rates of improvement or spontaneous
resolution in childrenwithOMEobserved after an episode of acute
otitis media (AOM) are much higher (Rosenfeld 2003). However,
recurrence of OME is also common, with an estimated rate of
50% within 24 months (Teele 1989).
In most cases, OME causes mild hearing impairment of short
duration. When experienced in early life and when episodes of
(bilateral) OME persist or recur, the associated hearing loss may
be significant and have a negative impact on speech development
and behaviour (Gouma 2011; Roberts 2004; Sabo 2003; Shekelle
2002).
Although the pathophysiology of OME is not fully understood,
both middle ear inflammation and Eustachian tube dysfunction
are likely to be contributory factors (Rovers 2004).
Description of the intervention
Since most cases of OME will resolve spontaneously, only chil-
dren with persistent middle ear effusion and associated hear-
ing loss potentially require treatment. To that end there are two
management options: surgical and non-surgical. There are two
Cochrane reviews addressing different surgical interventions: ven-
tilation tubes (grommets) (Browning 2010), and adenoidectomy
(van den Aardweg 2010). The combination of the two is addressed
in an individual patient data meta-analysis (Boonacker 2014).
The following non-surgical interventions have been addressed
in different Cochrane reviews: antihistamines and/or deconges-
tants (Griffin 2011), intranasal and oral corticosteroids (Simpson
2011), and nasal autoinflation (Perera 2013). A variety of antibi-
otics directed at themicrobial pathogens causing upper respiratory
tract infections are being used and are considered in this review.
How the intervention might work
The rationale for using antibiotics in OME is the potential bacte-
rial origin of the disease; a bacterial pathogen is identified in the
middle ear fluid of approximately one in three children with OME
(Poetker 2005). Successful eradication of bacteria may promote
faster resolution of middle ear fluid and prevention of secondary
complications. However, not all OME cases are of bacterial origin
and therefore the potential benefits of antibiotics need to be bal-
anced both against the well-recognised adverse effects and the in-
creased risk of bacterial resistance (Costelloe 2010; ECDC 2011;
Gillies 2015; Laxminarayan 2013).
Why it is important to do this review
In 2004, Rosenfeld reviewed the effects of antibiotic therapy in
OMEand concluded that there is evidence for a short-termbenefit,
but longer-term benefits are uncertain (Rosenfeld 2004). Mandel
et al came to a similar conclusion in their review (Mandel 2004).
After 2004, the effectiveness of antibiotics in the management
of OME had not been reviewed systematically until the original
publication of this review (van Zon 2012). This is an update of
that review.
O B J E C T I V E S
To assess the benefits and harms of oral antibiotics in children up
to 18 years with OME.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials (RCTs). We excluded quasi- and
cluster-RCTs. If cross-over trials were available, we only included
those where data from the first phase were available.
Types of participants
Children aged 18 years or under with a diagnosis of unilateral or
bilateral OME at time of randomisation. The clinical diagnosis
of OME had to be made by tympanometry alone or in combi-
nation with otoscopy (including pneumatic otoscopy and otomi-
croscopy). We excluded studies of children with ventilation tubes
present, those with chronic suppurative otitis media, known im-
munodeficiency, Down syndrome or craniofacial anomalies, in-
cluding cleft palate.
6Antibiotics for otitis media with effusion in children (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Types of interventions
Intervention
Oral antibiotics (of all types and courses of any duration).
Control
Placebo, no treatment or therapy of unproven effectiveness (an-
tihistamines, decongestants, mucolytics and intranasal corticos-
teroids). We excluded studies in which one antibiotic was com-
pared with another.
We analysed antihistamines, decongestants, mucolytics and in-
tranasal corticosteroids as the same comparator as placebo and no
treatment as they are not proven to be effective in children with
OME (Griffin 2011; Pignataro 1996; Simpson 2011).
Participants were allowed to receive additional medical therapies
provided such adjunct interventions were the same in the treat-
ment and in the control groups and that the additional therapies
were one of those of unproven effectiveness (see above).
Types of outcome measures
We analysed the outcomes listed below in the review, but we did
not use them as a basis for including or excluding studies.
Primary outcomes
• Complete resolution of OME (complete treatment success)
at two to three months post-randomisation.
This is defined as resolution of OME in the affected ear in children
with unilateral OME at randomisation and resolution of OME
in both ears in children with bilateral OME at randomisation;
in either case, the diagnosis having been made by tympanometry
alone or in combination with otoscopy.
• Adverse effects, specifically diarrhoea, vomiting or skin rash.
Secondary outcomes
• Complete resolution of OME (complete treatment success)
at all possible time points.
• Hearing level.
• Language and speech development.
• Cognitive development.
• Quality of life.
• Insertion of ventilation tubes.
• Tympanic membrane sequelae.
• AOM episodes.
Search methods for identification of studies
The Cochrane ENT Information Specialist conducted systematic
searches for randomised controlled trials and controlled clinical
trials. There were no language, publication year or publication
status restrictions. The date of the search was 14 April 2016.
Electronic searches
The Information Specialist searched:
• the Cochrane ENT Trials Register (searched 14 April 2016);
• the Cochrane Central Register of Controlled Trials
(CENTRAL 2016, Issue 3);
• PubMed (1946 to 14 April 2016);
• Ovid EMBASE (1974 to 2016 week 15);
• Ovid CAB Abstracts (1910 to 2016 week 13);
• EBSCO CINAHL (1982 to 14 April 2016);
• LILACS, lilacs.bvsalud.org (searched 14 April 2016);
• KoreaMed (searched via Google Scholar 14 April 2016);
• IndMed, www.indmed.nic.in (searched 14 April 2016);
• PakMediNet, www.pakmedinet.com (searched 14 April
2016);
• Web of Knowledge, Web of Science (1945 to 14 April
2016);
• ClinicalTrials.gov (searched via the Cochrane Register of
Studies 14 April 2016);
• World Health Organization (WHO) International Clinical
Trials Registry Platform (ICTRP), www.who.int/ictrp (searched
14 April 2016);
• ISRCTN, www.isrctn.com (searched 14 April 2016);
• Google Scholar, scholar.google.co.uk (searched 14 April
2016);
• Google, www.google.com (searched 14 April 2016).
In searches prior to 2015, we also searched BIOSIS Previews 1926
to February 2012.
The Information Specialist modelled subject strategies for
databases on the search strategy designed for CENTRAL. Where
appropriate, theywere combined with subject strategy adaptations
of the highly sensitive search strategy designed by Cochrane for
identifying randomised controlled trials and controlled clinical tri-
als (as described in theCochrane Handbook for Systematic Reviews of
Interventions Version 5.1.0, Box 6.4.b. (Handbook 2011). Search
strategies for major databases including CENTRAL are provided
in Appendix 1.
Searching other resources
We scanned the reference lists of identified publications for addi-
tional trials and contacted trial authors where necessary. In addi-
tion, the Information Specialist searched PubMed, The Cochrane
Library and Google to retrieve existing systematic reviews relevant
to this systematic review, so that we could scan their reference lists
for additional trials.
7Antibiotics for otitis media with effusion in children (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Data collection and analysis
This review is based on a published protocol (van Zon 2011). Any
differences between the published protocol and the (update of )
the review have been listed in the Differences between protocol
and review section.
Selection of studies
One review author independently screened titles and abstracts ob-
tained from the database searches. Two review authors reviewed
the full text of the potentially relevant titles and abstracts against
the inclusion and exclusion criteria.We resolved any disagreements
by discussion.
Data extraction and management
Two review authors independently extracted study characteristics
and outcomes from the included studies using standardised data
extraction forms. Any disagreements were resolved by discussion.
When information was insufficient, we contacted trial authors in
an attempt to obtain further information.
Assessment of risk of bias in included studies
Two authors independently assessed themethodological quality of
the included trials and resolved any disagreements by discussion.
We used the Cochrane ’Risk of bias’ tool, which involves describ-
ing each bias domain as reported in the trial and then assigning a
judgement about the adequacy of each entry: ’low’, ’high’ or ’un-
clear’ risk of bias.
Measures of treatment effect
We expressed dichotomous outcomes as a risk ratio (RR) with
accompanying 95% confidence intervals (CIs). For continuous
outcomes (i.e. mean hearing loss) we proposed to calculate mean
differences (MD) and their corresponding 95% CIs.
Unit of analysis issues
We identified one double-blind, cross-over trial. This trial was,
however, excluded since results were only reported after treatment
with both sulfisoxazole and placebo (i.e. data from the first phase
were not available).
Dealing with missing data
In case of missing data, we tried to contact the trial authors to
provide additional information.
Assessment of heterogeneity
We considered heterogeneity both clinically and statistically. We
assessed clinical heterogeneity of the included trials by reviewing
for potential differences between the trials in the types of partici-
pants recruited, interventions or control used, and how outcomes
were measured or reported (or both).
We assessed statistical heterogeneitywith visual inspectionof forest
plots and using the Chi2 test (with a significance level set at P value
< 0.10) and the I2 statistic, with I2 values over 50% suggesting
substantial heterogeneity (Handbook 2011).
Where there was substantial statistical heterogeneity, we carried
out pre-specified subgroup analyses and conducted sensitivity
analyses based on the risk of bias (see Subgroup analysis and
investigation of heterogeneity; Sensitivity analysis). Assessments of
potential differences in effect sizes between subgroups were based
on the Chi2 tests for heterogeneity between subgroups and with
visual inspection of forest plots. If none of these analyses com-
pletely resolved statistical heterogeneity then we employed a ran-
dom-effects (DerSimonian and Laird) model to provide a more
conservative effect estimate.
Assessment of reporting biases
For each included trial, we searched the internet and Clinical-
Trials.gov (http://clinicaltrials.gov/) for available study protocols.
Furthermore, we planned to consider reporting biases using a fun-
nel plot if a sufficient number of trials was identified (n > 20).
Data synthesis
We analysed the data by using an available case analysis according
the intention-to-treat (ITT) principle. In multi-arm studies we
only used data from the group treated with antibiotics and those
from the control group. If antibiotics were prescribed tomore than
one group, and no potentially effective additional treatments were
given, we combined data from these groups.
For dichotomous data, we calculated the RR with 95% CI using
theMantel-Haenszel method with a fixed-effect (I2 values < 50%)
or random-effects model. In addition, we calculated the number
needed to treat to benefit (NNTB) or number needed to treat to
harm (NNTH) based on the average risks of the control groups
in the included studies (’study population’) (Handbook 2011).
Subgroup analysis and investigation of heterogeneity
We planned to consider the following subgroup analyses if suffi-
cient data were available:
• age (< 2 years versus ≥ 2 years);
• duration of OME prior to study entry (< 3 months versus
≥ 3 months);
• definition of resolution of OME (tympanogram A versus A
and C1 versus A, C1 and C2);
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• laterality of OME (bilateral OME versus uni- or bilateral
OME);
• type of control intervention (placebo versus other); and
• duration of antibiotic treatment (< 4 weeks versus ≥ 4
weeks).
Sensitivity analysis
We performed a sensitivity analysis in which trials with high risk
of bias were excluded. We defined high risk of bias as a high risk
of allocation concealment or attrition bias.
GRADE and ’Summary of findings’ table
We used the GRADE approach to rate the overall quality of evi-
dence for each listed outcome, and to draw conclusions about the
quality of evidence. There are four possible ratings: high, moder-
ate, low and very low.
TheGRADE approach rates evidence fromRCTs that do not have
serious limitations as high quality.However, several factors can lead
to the downgrading of the evidence. The degree of downgrading
is determined by the seriousness of these factors:
• study limitations (risk of bias);
• inconsistency;
• indirectness of evidence;
• imprecision; and
• publication bias.
We included a ’Summary of findings’ table that contains what we
felt to be the sevenmost important outcomes: complete resolution
of OME at two to three months; adverse effects; complete resolu-
tion of OME at two to four weeks; complete resolution of OME
at more than six months; insertion of ventilation tubes; tympanic
membrane sequelae
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies.
Results of the search
This is an update of a Cochrane review first published in 2012
(van Zon 2012). In the first version of our review, 23 trials were
included. For this 2016 review, one additional trial was suitable
for inclusion. Furthermore, we included two studies that were
previously excluded on the basis that they did not report any of our
outcomes of interest andwe excluded one study thatwas previously
included on the basis that this was not a randomised controlled
trial. We therefore included 25 trials in this 2016 review (Figure
1). We did not identify any ongoing trials.
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Figure 1. Study flow diagram.
Included studies
Details of included studies can be found in the Characteristics of
included studies table.
Design
All 25 included trials were parallel-group design trials. Seven
(28%) were open-label trials, three (12%) were investigator-
blinded and 15 (60%) were double-blinded.
Participants and setting
The mean age of the included children was 4.7 years and 54%
were boys. Tympanometry was used in all trials and the majority
used a type B (60%) or type B or C2 (24%) tympanogram to
define OME. At baseline, the mean duration of OME was 10.6
weeks and 73% of children had bilateral disease.
The majority of trials (72%) were performed in secondary care.
Interventions
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The types of antibiotics most commonly used were amoxicillin
(six trials), trimethoprim-sulfamethoxazole (TMP-SMX; six tri-
als) and amoxicillin/clavulanic acid (five trials). Treatment dura-
tion varied across trials, but in the majority treatment duration
was 10 to 14 days (60%) or four weeks (24%) (Table 1). The
comparator was placebo in 52%. In four trials (16%) children in
both the antibiotic and comparator group also received intranasal
corticosteroids, an antihistamine, a decongestant or a combina-
tion of both.
Outcome measures
Two trials did not report on any of the outcomes of interest, leaving
23 trials (3258 children) that reported on at least one (Figure 1).
The type of tympanogramused todefine resolutionofOMEvaried
across trials, but most trials used a type A, C1 or C2 (48%), type
A or C1 (22%) or type A tympanogram (17%).
Excluded studies
We excluded a total of 42 studies; see Characteristics of excluded
studies.
Risk of bias in included studies
Details of the ’Risk of bias’ assessment of the included trials are
summarised in a ’Risk of bias’ graph (Figure 2) and summary
(Figure 3).
Figure 2. ’Risk of bias’ graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. ’Risk of bias’ summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
The method of random sequence generation was adequately de-
scribed in eight trials (32%), unclear in 16 trials (64%) and judged
inadequate in one trial (4%).
Concealment of allocation was adequately described in six trials
(24%), unclear in 18 trials (72%) and judged inadequate in one
trial (4%).
Blinding
We judged the risk of bias for blinding of participants and per-
sonnel to be low in 11 trials (44%), unclear in seven trials (28%)
and high in seven trials (28%). All included studies had a low risk
of bias for blinding of outcome assessment; resolution of OME
was in all studies based on tympanometry, an objective outcome
measure.
Incomplete outcome data
We judged the risk of bias for incomplete outcome data to be low
in 13 trials (52%), unclear in five trials (20%) and high in seven
trials (28%).
Selective reporting
We could not retrieve any of the trial protocols and could not
determine the risk of selective outcome reporting bias.
Other potential sources of bias
We judged the risk of other potential sources of bias to be unclear
in 21 trials (84%) and high in four trials (16%).
Effects of interventions
See: Summary of findings for the main comparison Antibiotics
compared to placebo, no treatment or therapy of unproven
effectiveness for otitis media with effusion in children
Primary outcomes
Complete resolution of otitis media with effusion (OME)
(complete treatment success) at two to three months post-
randomisation
We combined data from six trials (523 randomised children; 484
(93%) included in analysis). Children treated with oral antibiotics
were more likely to have complete resolution of OME at two to
three months post-randomisation than those allocated to control
treatment (risk ratio (RR) 2.00, 95% confidence interval (CI) 1.58
to 2.53; I2 = 33%, fixed-effect model, number needed to treat
to benefit (NNTB) 5) (Analysis 1.1; Figure 4). We did not find
evidence that the effects of antibiotics differed among subgroups
for this outcome.
Figure 4. Forest plot of comparison: 1 Antibiotics versus placebo, no treatment or therapy of unproven
effectiveness, outcome: 1.1 Complete resolution of OME at 2 to 3 months.
In the sensitivity analysis, where we excluded studies at high risk
of bias, the result was comparable with the effect observed in our
main analysis (RR 1.92, 95% CI 1.51 to 2.44; I2 = 44%, fixed-
effect model) (Analysis 2.1).
Quality of the evidence
We judged the evidence for this outcome to be ofmoderate quality;
we downgraded it from high to moderate quality due to study
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limitations (risk of bias).
Adverse effects, specifically diarrhoea, vomiting or skin rash
We combined data from five trials (775 randomised children; 742
(96%) included in analysis). Children treated with oral antibiotics
were more likely to experience adverse effects than those allocated
to control treatment (RR 2.15, 95% CI 1.29 to 3.60; I2 = 0%,
fixed-effect model; NNTH 20) (Analysis 1.2; Figure 5).
Figure 5. Forest plot of comparison: 1 Antibiotics versus placebo, no treatment or therapy of unproven
effectiveness, outcome: 1.2 Adverse effects.
In the sensitivity analysis, where we excluded studies at high risk
of bias, the result was comparable with the effect observed in our
main analysis (RR 1.97, 95% CI 1.16 to 3.35, I2 = 0%, fixed-
effect model) (Analysis 2.2).
Quality of the evidence
We judged the evidence for this outcome to be of low quality; we
downgraded it from high to low quality due to study limitations
(risk of bias) and inconsistency of effect estimates across individual
trials.
Secondary outcomes
Complete resolution of OME (complete treatment success)
at all possible time points
The duration of antibiotic treatment varied between studies (Table
1). The following analyses look at complete resolution of OME,
initially at fixed times post-randomisation irrespective of the dura-
tion of treatment (analyses a and b). The remaining analyses look
at the same outcomes at time points that also coincide with the
end of treatment (analyses c to f ).
a) Complete resolution of OME at two to four weeks (short-
term)
We combined data from 14 trials (2253 randomised children;
2091 (93%) included in analysis). Children treated with oral an-
tibiotics were more likely to have complete resolution of OME at
two to four weeks post-randomisation than those allocated to con-
trol treatment (RR 1.98, 95%CI 1.47 to 2.67; I2 = 71%, random-
effects model; NNTB 5) (Analysis 1.3). We found no evidence
that the effects of antibiotics differed among subgroups for this
outcome.
In the sensitivity analysis, where we excluded studies at high risk of
bias, the effect of antibiotics was somewhat larger than the effect
observed in our main analysis (RR 2.58, 95% CI 1.60 to 4.17; I2
= 76%, random-effects model) (Analysis 2.3).
Quality of the evidence
We judged the evidence for this outcome to be of low quality; we
downgraded it from high to low quality due to study limitations
(risk of bias) and inconsistency of effect estimates across individual
trials.
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b) Complete resolution of OME at more than six months
(long-term)
We combined data from five trials (668 randomised children; 606
(91%) included in analysis). Children treated with oral antibiotics
weremore likely to have complete resolution ofOME atmore than
six months post-randomisation than those allocated to control
treatment (RR 1.75, 95% CI 1.41 to 2.18; I2 = 32%, fixed-effect
model; NNTB6) (Analysis 1.4).We did not find evidence that the
effects of antibiotics differed among subgroups for this outcome.
In the sensitivity analysis, where we excluded studies at high risk
of bias, the result was comparable with the effect observed in our
main analysis (RR 2.13, 95% CI 1.30 to 3.50, I2 = 48%, fixed-
effect model) (Analysis 2.4).
Quality of the evidence
We judged the evidence for this outcome to be of low quality; we
downgraded it from high to low quality due to study limitations
(risk of bias) and inconsistency of effect estimates across individual
trials.
c) Complete resolution of OME at end of treatment (10 to 14
days treatment)
For this outcome, we could use data from six trials (1231 ran-
domised children; 1129 (92%) included in analysis). In this anal-
ysis one of the subgroup analyses showed a significant subgroup
difference: childrenwith persistentOME at study entry weremore
likely to have complete resolution of OME at the end of the treat-
ment period of 10 to 14 days when treated with oral antibiotics
than those with OME of any duration (RR 4.03, 95% CI 2.13 to
7.61; I2 = 0%, fixed-effect model; NNTB 4 versus RR 1.83, 95%
CI 1.38 to 2.44; I2 = 0%, fixed-effect model; NNTB 7, respec-
tively) (Analysis 1.5).
In the sensitivity analysis, where we excluded studies at high risk of
bias, the results were comparable with the effect estimates observed
in our main analysis (Analysis 2.5).
Quality of the evidence
We judged the evidence for this outcome to be of low quality; we
downgraded it from high to low quality due to study limitations
(risk of bias) and imprecise effect estimates across subgroups.
d) Complete resolution of OME at end of treatment (four
weeks treatment)
We combined data from four trials (534 randomised children; 479
(90%) included in analysis). Children treated with oral antibiotics
were more likely to have complete resolution of OME at the end
of the four-week treatment period than those allocated to control
treatment (RR 3.28, 95% CI 1.37 to 7.87; I2 = 79%, random-
effects model; NNTB 3) (Analysis 1.6). We found no evidence
that the effects of antibiotics differed among subgroups for this
outcome.
In the sensitivity analysis, where we excluded studies at high risk of
bias, the effect of antibiotics was larger than the effect observed in
our main analysis, but with a wider confidence interval (RR 9.19,
95%CI 4.29 to 19.70; I2 = 0%, fixed-effectmodel) (Analysis 2.6).
Quality of the evidence
We judged the evidence for this outcome to be of low quality; we
downgraded it from high to low quality due to study limitations
(risk of bias) and inconsistency of effect estimates across individual
trials.
e) Complete resolution of OME at end of treatment (three
months treatment)
We combined data from two trials (150 randomised children; 150
(100%) included in analysis). Children treated with oral antibi-
otics were more likely to have complete resolution of OME at
the end of the three-month treatment period than those allocated
to control treatment (RR 2.10, 95% CI 1.39 to 3.17; I2 = 44%,
fixed-effect model; NNTB 4) (Analysis 1.7). We did not deem
subgroup and sensitivity analyses to be useful because of the low
number of trials and included children.
Quality of the evidence
We judged the evidence for this outcome to be ofmoderate quality;
we downgraded it from high to moderate quality due to imprecise
effect estimates across individual trials.
f ) Complete resolution of OME at end of treatment (six
months treatment)
We combined data from two trials (203 randomised children; 196
(97%) included in analysis). Oral antibiotics were associated with
an increased chance of complete resolution of OME at the end of
the six-month treatment period, but the effect was not statistically
significant (RR 2.81, 95% CI 0.29 to 27.50; I2 = 64%, random-
effects model) (Analysis 1.8). We did not deem subgroup and
sensitivity analyses to be useful because of the low number of trials
and included children.
Quality of the evidence
We judged the evidence for this outcome to be of low quality; we
downgraded it from high to low quality due to study limitations
(risk of bias) and imprecise effect estimates across individual trials.
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Hearing level
Two studies reported hearing level based on speech recognition
thresholds at baseline and after two or four weeks follow-up.
At two weeks, Mandel 1991 reported a “statistically significant”
difference in mean speech recognition threshold between the an-
tibiotic and placebo groups: left ears 14.2 dB HL versus 18.5 dB
HL and right ears 14.0 dB HL versus 18.7 dB HL, respectively.
At four weeks, a “significant difference” was found between the
antibiotic and placebo groups only in the right ears (12.6 dB HL
versus 17.2 dB HL). The number of ears analysed was not re-
ported and insufficient data were available to calculate the mean
difference (MD) and 95% CI.
At four weeks, Mandel 1987 reported no statistically significant
differences in the mean speech recognition threshold between the
antibiotic and placebo groups: 14.9 dB HL versus 16.7 dB HL,
respectively.
Quality of the evidence
We judged the evidence for this outcome to be of low quality; we
downgraded it from high to low quality due to inconsistency of
effect estimates across individual trials and incomplete outcome
reporting.
Language and speech development
None of the trials reported data on language and speech develop-
ment.
Cognitive development
None of the trials reported data on cognitive development.
Quality of life
None of the trials reported data on quality of life.
Insertion of ventilation tubes
We combined data from two trials (144 randomised children; 121
(84%) included in analysis). Oral antibiotics were not associated
with a decrease in the proportion of children who had received
ventilation tubes comparedwith control treatment (RR0.90, 95%
CI 0.46 to 1.78; I2 = 0%, fixed-effect model) (Analysis 1.9). We
didnot deem subgroup and sensitivity analyses to be useful because
of the low number of trials and included children.
Quality of the evidence
We judged the evidence for this outcome to be of low quality; we
downgraded it from high to low quality due to risk of study limita-
tions (risk of bias) and imprecise effect estimates across individual
trials.
Tympanic membrane sequelae
For this outcome, data from one trial (103 randomised children;
103 (100%) included in analysis) were available (Leach 2008). In
this trial, amoxicillin given for six months was associated with a re-
duced risk for any tympanic membrane perforation during follow-
up as compared with placebo, but the effect was not statistically
significant (RR 0.42, 95% CI 0.18 to 1.01) (Analysis 1.10).
Quality of the evidence
We judged the evidence for this outcome to be of low quality; we
downgraded it from high to low quality due to concerns around
directness of evidence and imprecision.The trial included a limited
number of participants particularly at risk of suppurative otitis
media (Australian Aboriginal children in rural Australia).
Acute otitis media (AOM) episodes
Several studies looked for episodes of AOM in two different time
’windows’: in the first period of up to four to eight weeks and up
to six months.
AOM episodes within four to eight weeks
We combined data from five trials (1158 randomised children;
1086 (94%) included in analysis). Children treated with oral an-
tibiotics were less likely to experience AOM episodes within four
to eight weeks compared with those allocated control treatment
(RR 0.60, 95% CI 0.42 to 0.85; I2 = 0%, fixed-effect model;
NNTB 18) (Analysis 1.11). We did not find evidence that the
effects of antibiotics differed among subgroups.
In the sensitivity analysis, where we excluded studies at high risk of
bias, the effect of antibiotics was no longer statistically significant
(RR 0.70, 95% CI 0.37 to 1.31) (Analysis 2.7).
Quality of the evidence
We judged the evidence for this outcome to be of low quality; we
downgraded it from high to low quality due to study limitations
(risk of bias) and imprecise effect estimates across individual trials.
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AOM episodes within six months
We combined data from two trials (203 randomised children; 199
(98%) included in analysis). Children treated with oral antibiotics
were less likely to experience AOM episodes within six months
compared with those allocated control treatment (RR 0.56, 95%
CI 0.40 to 0.80; I2 = 61%, random-effects model; NNTB 5)
(Analysis 1.12).Wedidnot deem subgroup and sensitivity analyses
to be useful because of the low number of trials and included
children.
Quality of the evidence
We judged the evidence for this outcome to be of low quality; we
downgraded it from high to low quality due to study limitations
(risk of bias) and inconsistency of effect estimates across individual
trials.
D I S C U S S I O N
Summary of main results
We included 25 trials (3663 children), evaluating a range of an-
tibiotics, in a variety of different participants (varying in a number
of ways including severity of disease). Several different outcome
measures and time points for evaluation were used. Overall, we
assessed most studies as being at low risk of bias and the quality
of the evidence to be moderate.
We found moderate quality evidence that children with otitis me-
dia with effusion (OME) treated with oral antibiotics are more
likely to have complete resolution at two to three months post-
randomisation (primary outcome) than those allocated to control
treatment. However, there is evidence (albeit of low quality) in-
dicating that children treated with oral antibiotics are more likely
to experience diarrhoea, vomiting or skin rash (primary outcome)
than those allocated to the control treatment.
Whilst resolution of the middle ear effusion in OME - and the
restoration of a ventilated middle ear cleft - is undoubtedly desir-
able, for an individual patient it is important to know that this
is associated with an improvement in hearing. This is an assump-
tion that is often made and this does not seem to be an unreason-
able one. However, when the impact of antibiotics on short-term
hearing is actually evaluated in clinical trials, some uncertainty
remains. We only identified low quality evidence relating to this
outcome: that evidence is sparse and the results were inconclusive.
Furthermore, we did not identify any trials that looked at speech,
language and cognitive development or quality of life.
Overall completeness and applicability of
evidence
We believe that the studies included in this review include a com-
prehensive range of participants with a broad spectrum of disease
severity. Studies also cover several different antibiotics, periods of
treatment, outcome measures and follow-up times. As such, the
overall degree of completeness is high and the studies are sufficient
to address the objectives of the review.
’High-risk’ children (those at increased risk of speech, language
or learning problems and their consequences) are often excluded
from OME trials. However, we found nothing to make us suspect
that these children would particularly benefit from antibiotics.
Quality of the evidence
The quality of the evidence of the different outcomes varied from
moderate to low, mainly due to concerns about study limitations
(risk of bias), inconsistency and imprecision.
Potential biases in the review process
Since we used an extensive search strategy without language or
publication restrictions, it is unlikely that we have missed relevant
studies. In this 2016 update, we were able to retrieve the full text of
the two studies that were previously classified as ’studies awaiting
classification’ (Hozawa 2001; Yin 2002). Neither of these stud-
ies met our inclusion criteria. Data extraction and quality assess-
ment were both undertaken by two authors independently and we
strictly adhered to the instructions of the Cochrane Handbook for
Systematic Reviews of Interventions (Handbook 2011).
Agreements and disagreements with other
studies or reviews
The results of our systematic review are consistent with the ev-
idence underpinning the latest US guidelines (AAFP 2004) and
the meta-analysis by Rosenfeld 2004. Neither publication recom-
mends antibiotics for treating children with OME.
Our review differs from previous publications in the following
ways:
• We have included four trials published since 2004 (Ardehali
2008; Chen 2013; Choung 2008; Leach 2008).
• We have not only included trials with placebo as
comparator, but also trials comparing antibiotics to no treatment
or therapies of unproven effectiveness.
• We have included trials in which a prophylactic antibiotic
dose was used in the treatment group (de Castro 1982; Principi
1989; Thomsen 1989).
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A U T H O R S ’ C O N C L U S I O N S
Implications for practice
This review presents evidence of both benefits and harms associ-
ated with the use of antibiotics to treat children up to 16 years
with otitis media with effusion (OME). Although evidence indi-
cates that oral antibiotics are associated with an increased chance
of complete resolution of OME at various time points, we also
found evidence that these children are more likely to experience
diarrhoea, vomiting or skin rash. The impact of antibiotics on
short-term hearing is uncertain and low quality evidence did not
show that oral antibiotics were associated with fewer ventilation
tube insertions. Furthermore, we found no data on the impact of
antibiotics on other important outcomes such as speech, language
and cognitive development or quality of life.
Even in situations where clear and relevant benefits of antibiotics
have been demonstrated, these must always be carefully balanced
against the adverse effects and the emergence of bacterial resistance.
Immediate adverse effects of antibiotics such as gastrointestinal
upset and skin rash are common (Gillies 2015), and the emergence
of bacterial resistance has specifically been linked to the widespread
use of antibiotics for common conditions such as otitis media
(Costelloe 2010; ECDC 2011; Laxminarayan 2013).
Implications for research
We included 25 studies covering a comprehensive range of phar-
macological interventions, participants (with disease of varying
degrees of severity), outcome measures and follow-up. We believe
that further research will not provide added value to our current
findings.
However, since the demonstrable benefits of both surgery and
medical therapies inOME are limited, childrenwithOME-related
hearing loss that are at risk of speech and language and learning
problems deserve special attention. Further research to evaluate the
effectiveness of alternative strategies in these children in particular
is necessary.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Anari 1985
Methods Allocation: randomised
Design: parallel groups, open-label
Participants Number: 141 children (127 children included in analysis)
Age (mean): 4.6 years
Gender (%): 52% boys, 48% girls
Duration of OME at baseline (mean): unknown; OMEhad to last for at least 12 weeks
Laterality of disease at baseline (%): unknown
Setting: secondary care, Karlskrona, Sweden
Eligibility criteria:
1. Children below 12 years of age
2. OME in one or both ears, which lasted for at least 3 months, diagnosed by otomi-
croscopy (fluid behind intact ear drum) and type B tympanogram
Exclusion criteria: children with cleft palate, children treated with antibiotics because
of upper respiratory tract infection during the observation period
Interventions Intervention group 1: cefaclor 20 mg/kg/day in 2 divided doses for 10 days prior to
surgery; n = 46
Intervention group 2: cefaclor 20 mg/kg/day in a single dose 0.4 to 4 hours before
surgery; n = 50
Comparator group: no treatment; n = 45
Use of additional interventions: all children were placed on the waiting list for surgery
Outcomes Primary outcome: nasopharyngeal cultures collected during surgery
Funding sources No information provided
Declaration of interest No information provided
Notes Participants lost to follow-up total: 14/141 children (10%)
Participants lost to follow-up in Tx1 group: 14/46 children (30%)
Participants lost to follow-up in Tx2 group: 0/50 children (0%)
Participants lost to follow-up in control group: 0/45 children (0%)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method not described
Allocation concealment (selection bias) Unclear risk Method not described
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Anari 1985 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Not blinded, objective primary outcome
(nasopharyngeal culture)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 10% participants lost to follow-up, all in
treatment group
Selective reporting (reporting bias) Unclear risk Noprotocol available; insufficient informa-
tion to permit a judgement of low or high
risk
Other bias Unclear risk Baseline characteristics: imbalance (age)
Unclear whether they used ITT analysis
No formal sample size calculations were
performed
Use of co-interventions: no information
provided
Compliance with treatment: no informa-
tion provided
Ardehali 2008
Methods Allocation: randomised
Design: parallel groups, investigator-blinded
Participants Number: 90 children (no patients were excluded; 60 children were eligible for inclusion
in this review)
Age (mean): 5.4 years
Gender (%): 51% boys, 49% girls
Duration of OME at baseline (mean): unknown; OMEhad to last for at least 12 weeks
Laterality of disease at baseline (%): unknown
Setting: secondary care, Teheran, Iran
Eligibility criteria:
1. Children aged 2 to 12 years
2. Chronic OME that lasted for at least 3 months documented by clinical examination
by 2 separate ENT surgeons and type B or C2 tympanogram in at least one ear without
clinical signs and symptoms of active infection that were refractory to 3 periods of
antibacterial treatment
Exclusion criteria: past medical history of disorders that are known to be associated
with an increased prevalence of recurrent otitis media, otitis media with effusion with
unknown aetiology such as Down Syndrome, cleft palate, neurodevelopmental delay,
patients with genetic or congenital palate, craniofacial malformations, previous ventila-
tion tubes or adenoidectomy, immunodeficiency, cholesteatoma, sensorineural hearing
loss or other medical conditions (renal, liver or cardiac illnesses)
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Ardehali 2008 (Continued)
Interventions Intervention group 1: amoxicillin-clavulanic acid 40 mg/kg/day in 3 divided doses
(maximum 750 mg/day) for 3 months; n = 30
Intervention group 2: cisapride 1 mg/kg/day for 3 months; n = 30; this group was not
included in our analyses
Comparator group: no treatment for 3 months; n = 30
Use of additional interventions: none described
Outcomes Primary outcome: complete resolution of OME at 3 months based on clinical examina-
tion and tympanometry (type A or C1 tympanogram) assessed by 2 unique independent
ENT surgeons blinded to participant group assignment
Secondary outcome: adverse effects
All patients were followed up every month for 3 months
Funding sources No information provided
Declaration of interest No information provided
Notes Participants lost to follow-up total: 0/90 children (0%)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation
schedule
Allocation concealment (selection bias) Unclear risk Method not described
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Single-blind; only personnel were blinded
during treatment
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcome determined by 2 unique ENT
surgeons blinded to assignment. Primary
outcome based on objective tympanometry
Incomplete outcome data (attrition bias)
All outcomes
Low risk No patients lost to follow-up
Selective reporting (reporting bias) Unclear risk Noprotocol available; insufficient informa-
tion to permit a judgement of low or high
risk
Other bias Unclear risk Baseline characteristics: balanced
Unclear whether they used ITT analysis
No formal sample size calculations were
performed
Use of co-interventions: no information
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Ardehali 2008 (Continued)
provided
Compliance with treatment: no informa-
tion provided
Balle 1990
Methods Allocation: randomised
Design: parallel groups, double-blind
Participants Number: 264 children (221 children included in analysis)
Age (mean): ? (range 1 to 10 years)
Gender (%): 52% boys, 48% girls
Duration of OME at baseline (mean): unknown; OMEhad to last for at least 12 weeks
Laterality of disease at baseline (%): unknown
Setting: secondary care, Copenhagen, Denmark
Eligibility criteria:
1. Children aged 1 to 10 years
2. OME defined as type B or C2 tympanogram in one or both ears for at least 3 months
Exclusion criteria: allergy to penicillin
Interventions Intervention group: amoxicillin-clavulanic acid for 4 weeks (children aged 1 to 5: 5 ml
3 times a day and children 6 to 10: 7.5 ml 3 times a day); n = 131
Comparator group: placebo; n = 133
Use of additional interventions: no concomitant medication other than analgesics was
allowed during the treatment period
Outcomes Primary outcome: nasopharyngeal cultures collected prior to and after termination of
treatment and every month for the next 11 months
Funding sources Astra Medical company supplied the antibiotic and supported the study
Declaration of interest No information provided
Notes Participants lost to follow-up total: 43/264 children (16%)
Participants lost to follow-up in Tx group: 22/131 children (17%)
Participants lost to follow-up in control group: 21/133 children (16%)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method not described
Allocation concealment (selection bias) Unclear risk Method not described
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Balle 1990 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Stated to be double-blind; no further infor-
mation provided
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Stated to be double-blind. Objective pri-
mary outcome (nasopharyngeal culture)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 16% participants lost to follow-up
Selective reporting (reporting bias) Unclear risk Noprotocol available; insufficient informa-
tion to permit a judgement of low or high
risk
Other bias Unclear risk Baseline characteristics: balanced
Unclear whether they used ITT analysis
No formal sample size calculations were
performed
Use of co-interventions: not permitted
other than analgesics
Compliance with treatment: assessed from
contents of the returnedmedication bottles
Chen 2013
Methods Allocation: randomised
Design: parallel groups, open-label
Participants Number: 84 children (73 followed up for 12 weeks)
Age (mean): 5.6 years
Gender (%): 58% boys, 42% girls
Duration of OME at baseline (mean): 1.5 weeks
Laterality of disease at baseline (%): 45% bilateral disease
Setting: secondary care, ENT department in the First Affiliated Hospital, Sun Yat-Sen
University, Guangzhou, China
Eligibility criteria:
1. Children aged 3 to 14 years
2. OME with a duration of less than 3 months defined as aural fullness, hearing loss
or tinnitus together with integrity, invagination or fluid level of tympanic membrane at
otoscopy and tympanometry (type B or C2 tympanogram)
Exclusion criteria: suppurative otitis media, tympanic membrane perforation, adenoid
hypertrophy, tumour, severe systemic diseases and allergy or intolerance to macrolides
Interventions Intervention group: clarithromycin; firstweek 15mg/kg/day divided in 2 doses followed
by 5 to 8 mg/kg/day divided in 4 doses until the tympanogram was type A; n = 42
Comparator group: no antibiotics (intranasal corticosteroids only); n = 42
Use of additional interventions: all participants were prescribed intranasal corticos-
teroids (type of corticosteroid not described)
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Chen 2013 (Continued)
Outcomes Primary outcome: complete resolution of OME at 3 months based on tympanometry
(type A tympanogram)
Secondary outcomes: hearing levels, number of ventilation insertions because of treat-
ment failure, adverse effects
All patients were followed up every 2 weeks with hearing and tympanometry. Routine
nasal endoscopy was performed to exclude possible nasal diseases
Funding sources The study was supported by grants from National Basis Research Program of China,
National Natural Science fund of China and Key Nature Fund of Guangdong Province
Declaration of interest None declared
Notes Participants lost to follow-up total: 11/84 children (13%)
Participants lost to follow-up in antibiotic group: 6/42 children (14%)
Participants lost to follow-up in control group: 5/42 children (12%)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method not described
Allocation concealment (selection bias) Unclear risk Method not described
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Not blinded. Primary outcome based on
objective tympanometry
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 13% of children lost to follow-up
Selective reporting (reporting bias) Unclear risk Noprotocol available; insufficient informa-
tion to permit a judgement of low or high
risk
Other bias Unclear risk Baseline characteristics: balanced
Unclear whether they used ITT analysis
No formal sample size calculations were
performed
Use of co-interventions: all participants
were prescribed intranasal corticosteroids
Compliance with treatment: quote “all the
rest patients completed the entire course of
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Chen 2013 (Continued)
treatment”
Choung 2008
Methods Allocation: randomised
Design: parallel groups, open-label
Participants Number: 100 children (83 followed up for a mean period of 6.9 weeks)
Age (mean): 5.8 years
Gender: 68% boys, 32% girls
Duration of OME at baseline (mean): 10.5 weeks
Laterality of disease at baseline (%): 81% bilateral disease
Setting: tertiary care, ENT department Ajou University Hospital, Suwon, Korea
Eligibility criteria:
1. Children aged 5 months to 12 years
2. OME diagnosed by pneumatic otoscopy, tympanometry and pure tone audiometry.
Children needed to have a type B, C1 or C2 tympanogram and a hearing loss greater
than 25 dB on pure tone audiometry
Exclusion criteria: children with AOM and fever or otalgia, children with cleft palates,
developmental difficulties, contraindications to medications
Interventions Duration of treatment: 2 weeks
Intervention group 1: amoxicillin-clavulanic acid syrup 1 cc/kg; n = ? (n = 16 included
in analysis)
Intervention group 2: amoxicillin-clavulanic acid syrup 1 cc/kg plus prednisolone 1
mg/kg; n = ? (n = 18 included in analysis); this group was not included in our analyses
Intervention group 3: amoxicillin-clavulanic acid syrup 1 cc/kg plus ebastine 0.2 cc/
kg; n = ? (n = 15 included in analysis)
Intervention group 4: amoxicillin-clavulanic acid syrup 1 cc/kg plus prednisolone 1
mg/kg plus ebastine 0.2 cc/kg; n = ? (n = 17 included in analysis); this group was not
included in our analyses
Comparator group:mucolytic ivy leaf extract; n = ? (n = 17 included in analysis)
Use of additional interventions: not described
Outcomes Primary outcomes: complete resolution of OME at 6 months by pneumatic otoscopy,
pure tone audiometry and tympanometry (type A tympanogram) and VT insertion
(hearing loss greater than 40 dB, bilateral OME for more than 3 months, unilateral
OME for more than 6 months)
All patients were followed up every 2 weeks with pure tone audiometry and tympanom-
etry. Children with hearing loss less than 40 dB and bilateral OME were observed for 3
months and those with hearing loss less than 40 dB and unilateral OME were observed
for 6 months
Funding sources No information provided
Declaration of interest No information provided
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Choung 2008 (Continued)
Notes Participants lost to follow-up total: 17/100 children (17%); no further information
provided
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method not described
Allocation concealment (selection bias) Unclear risk Method not described
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Not blinded. Primary outcome based on
objective tympanometry
Incomplete outcome data (attrition bias)
All outcomes
High risk Total of randomised children per subgroup
not reported
17 randomised children were not used for
analysis; only 16 children were reported as
lost to follow-up
Selective reporting (reporting bias) Unclear risk Noprotocol available; insufficient informa-
tion to permit a judgement of low or high
risk
Other bias Unclear risk Baseline characteristics: balanced
Unclear whether they used ITT analysis
No formal sample size calculations were
performed
Use of co-interventions: no information
provided
Compliance with treatment: no informa-
tion provided
Corwin 1986
Methods Allocation: randomised
Design: parallel groups, investigator-blinded
Participants Number: 149 children (131 followed up for 1 month)
Age (median): 3.4 years
Gender: unknown
Duration of OME at baseline (mean): unknown
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Corwin 1986 (Continued)
Laterality of disease at baseline (%): 46% bilateral disease
Setting: secondary care, Department of Pediatrics SUNY Upstate Medical Center, New
York, USA
Eligibility criteria:
1. Children aged 5 months to 16 years
2. Persistent MEE at 1 month after diagnosis of AOM defined otoscopically as immobile
or minimally mobile tympanic membrane, which was in neutral or retracted position
and had a grey or opalescent colour. In children over 2 years of age the diagnosis was
confirmed with tympanometry
Exclusion criteria: history of 3 or more AOM episodes during previous year, antibiotic
prophylaxis, chronic middle ear effusion
Interventions Intervention group: erythromycin ethylsuccinate 50 mg/kg/day and sulfisoxizole 150
mg/kg/day for 10 days; n = 75
Comparator group: no treatment; n = 74
Use of additional interventions: children with repeat episodes of acute otitis media
prior to the follow-up visit were treated with antibiotics; no further information provided
Outcomes Primary outcome: complete resolution of OME at 1 month based on pneumatic oto-
scopy and tympanometry (no further details provided on the definition of complete
OME resolution)
Funding sources No information provided
Declaration of interest No information provided
Notes Participants lost to follow-up total: 18/149 children (12%)
Participants lost to follow-up in antibiotic group: 9/75 children (12%)
Participants lost to follow-up in control group: 9/74 children (12%)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Table of random numbers
Allocation concealment (selection bias) Unclear risk Method not described
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Single-blind; only personnel were blinded
during treatment
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcome determined by nurse practition-
ers blinded to assignment. Primary out-
come based on objective tympanometry
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 12% of children lost to follow-up
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Corwin 1986 (Continued)
Selective reporting (reporting bias) Unclear risk Noprotocol available; insufficient informa-
tion to permit a judgement of low or high
risk
Other bias Unclear risk Baseline characteristics: balanced
Unclear whether they used ITT analysis
No formal sample size calculations were
performed
Use of co-interventions: no information
provided
Compliance with treatment: no informa-
tion provided
Daly 1991
Methods Allocation: randomised, stratified on 3 prognostic variables (age at first episode, day-
care attendance, duration of otitis media with effusion)
Design: parallel groups, double-blind
Participants Number: 42 children (42 followed up for 1 month)
Age (mean): 2.8 years
Gender: 60% boys, 40% girls
Duration of OME at baseline (mean): 6.4 weeks
Laterality of disease at baseline (%): 100% bilateral disease
Setting: secondary care, suburban multispecialty clinic, Minneapolis, USA
Eligibility criteria:
1. Children aged 6 months to 8 years
2. 2 or more physician-documented AOM episodes in previous 18 months
3. Last documentation of AOM or OME no more than 4 weeks prior to enrolment
4. Appropriate antibiotic treatment for the most recent acute otitis media episode
5. Immunisations appropriate for age
6. BilateralOMEbased on an algorithmusingfindings fromotoscopy and tympanometry
and one or both of the following: day-care attendance for at least 15 hours a week with
5 or more children or otitis media with effusion for at least 4 weeks at enrolment as
documented in the medical record
Exclusion criteria: allergy to trimethoprim, sulfonamides, ampicillin, amoxicillin or
oral corticosteroids, significant chronic disease of kidney, heart, liver or immune system,
hypertension, ventilation tubes, concomitant infection or varicella exposure in the pre-
ceding 3 weeks without a previous history of varicella
Interventions Intervention group: TMP-SMX 8 mg and 40 mg/day in 2 doses for 2 weeks; n = 21
Comparator group: placebo for 2 weeks; n = 21
Use of additional interventions: children who experienced AOMduring the treatment
phase were discontinued from study medication and treated with amoxicillin 40 mg/kg/
day divided into 3 daily doses for 10 days
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Daly 1991 (Continued)
Outcomes Primary outcome: complete resolution of OME at 1 month based on pneumatic oto-
scopy and tympanometry (type A, C1 or C2 tympanogram)
Secondary outcome: adverse effects
Funding sources Active and placebo drugs were provided by Burroughs Wellcome Co. and The Upjohn
Company. The work was supported in parts by grants from The Upjohn Company,
BurroughsWellcomeCo.,MinnesotaMedical Foundation and the ParkNicolletMedical
Center Research Foundation
Declaration of interest No information provided
Notes Participants lost to follow-up total: 0/42 children (0%)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Allocation scheme to achieve balanced as-
signment
Group assignment was determined by the
study identification number
Allocation concealment (selection bias) Low risk The allocation schemewas unknown to the
research nurse and examining physicians
and allocation was performed by the clinic
pharmacy (pharmacy-controlled)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind, placebo-controlled fashion.
Placebos were similar in taste and appear-
ance to the active drugs
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double-blind, placebo-controlled fashion.
Primary outcome based on objective tym-
panometry
Incomplete outcome data (attrition bias)
All outcomes
Low risk Nochildren lost to follow-up (andno cross-
overs)
Selective reporting (reporting bias) Unclear risk Noprotocol available; insufficient informa-
tion to permit a judgement of low or high
risk
Other bias Unclear risk Baseline characteristics: balanced
Unclear whether they used ITT analysis
No formal sample size calculations were
performed
Use of co-interventions: no information
provided
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Daly 1991 (Continued)
Compliance with treatment: 89% in both
groups as measured by diary, bottle method
and serum assay for sulfamethoxazole
de Castro 1982
Methods Allocation: randomised
Design: parallel groups, double-blind
Participants Number: 30 children (30 followed up for 1 month)
Age (mean): unknown (range 3 to 6 years)
Gender: 63% boys, 37% girls
Duration of OME at baseline (mean): unknown
Laterality of disease at baseline (%): unknown
Setting: all children were living in a home for abused and/or neglected children, St.
Louis, USA
1. Children aged 3 to 6 years
2. Bilateral otitis media with effusion of any duration based on otoscopy, pure tone
audiometry and tympanometry (type B, C1 or C2 tympanogram)
Exclusion criteria: none
Interventions Intervention group: sulfisoxazole 40 mg/kg/day for 4 weeks; n = 15
Comparator group: placebo for 4 weeks; n = 15
Use of additional interventions: no information provided
Outcomes Primary outcome: complete resolution of OME at 1 month based on otoscopy, pure
tone audiometry and tympanometry (type A tympanogram)
Funding sources No information provided
Declaration of interest No information provided
Notes Participants lost to follow-up total: 0/30 children (0%)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method not described
Allocation concealment (selection bias) Unclear risk Method not described
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Stated to be double-blinded, but insuffi-
cient information provided on how blind-
ing was ensured
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de Castro 1982 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Stated to be double-blinded. Primary out-
come based on objective tympanometry
Incomplete outcome data (attrition bias)
All outcomes
Low risk No children lost to follow-up
Selective reporting (reporting bias) Unclear risk Noprotocol available; insufficient informa-
tion to permit a judgement of low or high
risk
Other bias Unclear risk Baseline characteristics: no information
provided
Unclear whether they used ITT analysis
No formal sample size calculations were
performed
Use of co-interventions: no information
provided
Compliance with treatment: quote “com-
pliance with treatment was excellent (96.
2%)”
Ernstson 1985
Methods Allocation: randomised
Design: parallel groups, open-label
Participants Number: 91 children (91 followed up for median 3 weeks (range 2 to 5))
Age (mean): 4.7 years
Gender: 49% boys, 51% girls
Duration of OME at baseline (mean): unknown
Laterality of disease at baseline (%): 70% bilateral disease
Setting: secondary care, Karlskrona, Sweden
Eligibility criteria:
1. Children aged 12 years and below
2. Chronic OME (> 3 months) in one or both ears diagnosed by otomicroscopy showing
fluid behind an intact ear drum and tympanometry (type B tympanogram)
Exclusion criteria: children with cleft palate, upper respiratory tract infection during
the period of observation, antibiotics in previous 4 weeks
Interventions Intervention group: cefaclor 20 mg/kg/day in 2 doses for the last 10 days prior to the
day scheduled for surgery; n = 46
Comparator group: untreated for the time from the decision to operate to the day
appointed for surgery; n = 45
Use of additional interventions: children that had not healed in both ears at day of
surgery underwent myringotomy with or without insertion of ventilation tubes. No
further information provided
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Ernstson 1985 (Continued)
Outcomes Primary outcome: complete resolution of OME at 3 weeks (range 2 to 5 weeks) based
on otomicroscopy and tympanometry (type A or C1 tympanogram)
Secondary outcome: proportion of children with a relapse after complete resolution of
OME at 10 to 27 months (median 20 months)
Funding sources No information provided
Declaration of interest No information provided
Notes Participants lost to follow-up total: 0/91 children (0%)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method not described
Allocation concealment (selection bias) Unclear risk Method not described
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Not blinded. Primary outcome based on
objective tympanometry
Incomplete outcome data (attrition bias)
All outcomes
Low risk No children lost to follow-up
Selective reporting (reporting bias) Unclear risk Noprotocol available; insufficient informa-
tion to permit a judgement of low or high
risk
Other bias Unclear risk Baseline characteristics: imbalance (gen-
der)
Unclear whether they used ITT analysis
No formal sample size calculations were
performed
Use of co-interventions: no information
provided
Compliance with treatment: no informa-
tion provided
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Giebink 1990
Methods Allocation: randomised
Design: parallel groups, open-label
Participants Number: 76 children (72 included in analysis)
Age (mean): 3.8 years
Gender: 60% boys, 40% girls
Duration of OME prior at baseline (mean): 9.5 weeks
Laterality of disease at baseline (%): unknown
Setting: secondary care, Minneapolis, USA
Eligibility criteria:
1. Children aged 10 months to 8 years
2. 3 or more otitis media episodes within the previous 18 months
3. An episode of AOM or asymptomatic OME diagnosed 10 to 28 days before entry
4. Completion of at least 10 days of antimicrobial treatment for the most recent AOM
episode
5. OME documented by otoscopy and tympanometry at entry and 3 and 6 weeks after
entry (children entered the study 6 weeks before they were randomised)
Exclusion criteria: history of adverse reactions to sulfonamides, presence of ventilation
tubes, acute otitis media
Interventions Intervention group: TMP-SMX suspension 8 mg and 40 mg/kg/day in 2 doses for 4
weeks; n = ? (n = 20 included in analysis)
Intervention group 2: ibuprofen suspension 24 mg/kg/day in 4 doses for 2 weeks; n =
? (n = 15 included in analysis); this group was not included in our analyses
Intervention group 3: prednisone tablets 1 mg/kg/day in 2 doses for 7 days, followed
by 0.5 mg/kg/day in 2 doses for 4 days, followed by 0.12 mg/kg/day in 1 dose for 3 days;
n = ? (n = 18 included in analysis); this group was not included in our analyses
Comparator group: no treatment; n = ? (n = 19 included in analysis)
Use of additional interventions: no other medications, including antihistamines, de-
congestants and antipyretics, were prescribed; parents were advised not to use any other
medication, including over-the-counter preparations, during the 4 weeks after randomi-
sation
Outcomes Primary outcome: complete resolution of OME at 2 and 4 weeks after randomisation
based on an algorithm in which results from pneumatic otoscopy, middle ear muscle
reflex and impedance audiometry were used (type A, C1 or C2 tympanogram)
Secondary outcome: treatment failure (OME in at least one ear at both the 2- and 4-
week post-randomisation visits or continuous OME for 10 weeks during follow-up after
initially resolving OME), AOM relapse within 8 weeks after randomisation, insertion
of ventilation tubes, OME duration, hearing levels, adverse effects
* Data on insertion of ventilation tubes and hearing levels not suitable for inclusion in
this review
Funding sources Supported in parts by grants from the Robert Wood Johnson Foundation, The Upjohn
Company and Burroughs Wellcome Company and a programme project grant (8P50-
CD-00133) from the National Institute of Deafness and Other Communicative Disor-
ders
Declaration of interest No information provided
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Giebink 1990 (Continued)
Notes Participants lost to follow-up total: 4/76 children (5%); no further information pro-
vided
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method not described
Allocation concealment (selection bias) Unclear risk Method not described
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Not blinded. Primary outcome based on
objective tympanometry
Incomplete outcome data (attrition bias)
All outcomes
High risk Total of randomised children per subgroup
not reported
5% of children lost to follow-up
Selective reporting (reporting bias) Unclear risk Noprotocol available; insufficient informa-
tion to permit a judgement of low or high
risk
Other bias Unclear risk Baseline characteristics: balanced
Unclear whether they used ITT analysis
No formal sample size calculations were
performed
Use of co-interventions: no other medica-
tion prescribed, parents were advised not
to use any medication during the 4 weeks
after randomisation
Compliance with treatment: high compli-
ance rates; monitored by parental diary and
bymeasuring the remaining medication af-
ter treatment
Healy 1984
Methods Allocation: randomised
Design: parallel groups, open-label
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Healy 1984 (Continued)
Participants Number: 200 children (189 included in analysis)
Age (mean): unknown (range 2 to 5 years)
Gender: 61% boys, 39% girls
Duration of OME prior at baseline (mean): unknown; OME had to last for at least 6
weeks
Laterality of disease at baseline (%): 79% bilateral disease
Setting: secondary care, Boston, USA
Eligibility criteria:
1. Children aged 2 to 5 years
2. OME for at least 6 weeks documented by pneumatic otoscopy, middle ear muscle
reflex and tympanometry (type B, C1 or C2 tympanogram)
Exclusion criteria: history of ENT surgery, middle ear abnormality such as adhesive
otitis media, tympanic membrane perforation or cholesteatoma, facial anomalies or
congenital syndromes, upper respiratory infection in previous 4 weeks, systemic illness
such as cystic fibrosis, acute suppurative otitis media, sinusitis, a strong family history of
allergy or history of having received medical therapy of their MEE within the previous
4 weeks (including sympathomimetic amines, antihistamines or antibiotics)
Interventions Intervention group: TMP-SMX suspension 8 mg and 40 mg/kg/day in 2 doses for 4
weeks; n = 100
Comparator group: observation; n = 100
Use of additional interventions: not described
Outcomes Primary outcome: complete resolution ofOME at 4weeks after randomisation based on
pneumatic otoscopy, middle ear muscle reflex and tympanometry (type A tympanogram)
Secondary outcomes: complete or partial resolution of OME at 4 weeks, AOM at 4
weeks
Funding sources No information provided
Declaration of interest No information provided
Notes Participants lost to follow-up total: 11/200 children (6%)
Participants lost to follow-up in antibiotic group: 4/100 children (4%)
Participants lost to follow-up in control group: 7/100 children (7%)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk The author would simply call a disinter-
ested person who would pull a previously
randomly arranged card that would show
the word either “control” or “antibiotic”
Allocation concealment (selection bias) Low risk Allocation concealment was ensured as a
disinterested person performed the ran-
domisation
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Healy 1984 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Not blinded. Primary outcome based on
objective tympanometry
Incomplete outcome data (attrition bias)
All outcomes
Low risk 7% of children lost to follow-up
Selective reporting (reporting bias) Unclear risk Noprotocol available; insufficient informa-
tion to permit a judgement of low or high
risk
Other bias Unclear risk Baseline characteristics: balanced
Unclear whether they used ITT analysis
No formal sample size calculations were
performed
Use of co-interventions: no information
provided
Compliance with treatment: high compli-
ance rates; monitored by parental admin-
istration of the medication on a daily cal-
endar and investigation of the bottles re-
turned by parents
Hemlin 1997
Methods Allocation: randomised (3:3:1 ratio)
Design: parallel groups, double-blind, double-dummy
Participants Number: 142 children (140 included in analysis)
Age (mean): 5.3 years
Gender: 62% boys, 38% girls
Duration of OME prior at baseline (mean): unknown; OME had to last for at least
12 weeks
Laterality of disease at baseline (%): 86% bilateral disease
Setting: secondary care, Karolinska Hospital, Sweden
Eligibility criteria:
1. Children aged 2 to 12 years
2. Unilateral or bilateral OME for at least 3 months documented by otomicroscopy and
tympanometry (type B tympanogram in at least one of the ears)
Exclusion criteria: severe underlying disease, immunologic deficiency, cleft palate,
known or suspected allergy to penicillins or cephalosporins, a history of an antibacterial
treatment within the prior 4 weeks, previous inclusion in the study
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Hemlin 1997 (Continued)
Interventions Intervention group: cefexime suspension 8 mg/kg/day in 2 doses for 10 days; n = 62
Intervention group 2: cefexime 8 mg/kg/day in 2 doses for 10 days + betamethasone 6
mg single dose at day 10; n = 60; this group was not included in our analyses
Comparator group: placebo suspension for 10 days + placebo tablet at day 10; n = 20
Use of additional interventions: antimicrobial agents other than the study drugs were
not allowed but any other medications considered necessary for the patient’s welfare were
allowed
Outcomes Primary outcome: partial or complete resolution of OME at 2 to 11 days after comple-
tion of the trial (days 12 to 21) based on otomicroscopy and tympanometry defined as
a normal middle ear status (type A, C1 or C2 tympanogram) in at least one ear (in case
of bilateral OME at baseline) or both ears (in case of unilateral OME at baseline)
Secondary outcomes: OME relapses at 6 weeks and 6 months, adverse effects
Funding sources ASTRAAB supplied the drugs and patient registration forms and assisted in data-analysis
Declaration of interest No information provided
Notes Participants lost to follow-up total: 2/142 children (1%)
Participants lost to follow-up in antibiotic group: 1/62 children (2%)
Participants lost to follow-up in control group: 0/20 children (0%)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “The drugs were dispensed double-
blind by a double-dummy technique”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double-blind. Primary outcome based on
objective tympanometry
Incomplete outcome data (attrition bias)
All outcomes
Low risk 1% of children lost to follow-up
Selective reporting (reporting bias) Unclear risk Protocol not available; insufficient infor-
mation to permit a judgement of low or
high risk
Other bias Unclear risk Baseline characteristics: balanced
Unclear whether they used ITT analysis
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Hemlin 1997 (Continued)
Formal sample size calculations were per-
formed
Use of co-interventions: antimicrobial
agents other than the study drugs were not
allowed but any other medications consid-
ered necessary for the patient’s welfare were
allowed
Compliance with treatment: compliance
was determined (described inmaterials and
methods), but not presented in manuscript
Leach 2008
Methods Allocation: randomised (block-randomisation)
Design: parallel groups, double-blind
Participants Number: 103 children (103 included in analysis)
Age (mean): 3.7 months
Gender: 52% boys, 48% girls
Duration of OME prior at baseline (mean): unknown
Laterality of disease at baseline (%): unknown
Setting: Aboriginal community located 70 km from Darwin, Australia
Eligibility criteria:
1. Children below 12 months of age
2. Unilateral or bilateral OME documented by pneumatic otoscopy and tympanometry
(type B tympanogram)
Exclusion criteria: prematurity (< 34 weeks), chronic infection requiring prophylactic
antibiotic therapy, craniofacial abnormalities or immune deficiency syndromes
Interventions Intervention group: amoxicillin 50 mg/kg/day in 2 doses for 24 weeks; n = 52 (n = 52
included in analysis)
Comparator group: placebo for 24 weeks; n = 51 (n = 51 included in analysis)
Use of additional interventions: intercurrent illnesses were managed according to local
community treatment guidelines
Outcomes Primary outcome: complete resolution of OME at 2 consecutive monthly visits based
on pneumatic otoscopy and tympanometry (type A, C1 or C2 tympanogram)
Secondary outcomes: complete resolution of OME at 6 months, AOM at 6 months,
tympanic membrane sequelae (perforation) at 6 months
Infants were examinedmonthly over the 24-week intervention period or until “treatment
success” (complete resolution of OME at 2 consecutive monthly visits) was documented
Funding sources The NHMRC and the Menzies School of Research funded the authors
Declaration of interest None declared
Notes Participants lost to follow-up total:2/103 children (2%); all 103 childrenwere included
in analyses
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Leach 2008 (Continued)
Participants lost to follow-up in antibiotic group: 0/52 children (0%)
Participants lost to follow-up in control group: 2/51 children (4%)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Block-randomisation (n = 7) stratified by
age (< 6 months versus > 6 months) using
computer-generated random numbers
Allocation concealment (selection bias) Low risk Quote: “Allocation to placebo or amoxi-
cillin, and the use and size of block-ran-
domisation was concealed from investiga-
tors until data collection was completed.”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind. Quote: “Blinding
was achieved by using a placebo similar in
packaging, colour, consistency and smell to
amoxicillin suspension.”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double-blind. Primary outcome based on
objective tympanometry
Incomplete outcome data (attrition bias)
All outcomes
Low risk 2% of children lost to follow-up; all ran-
domised children were included in analyses
Selective reporting (reporting bias) Unclear risk Noprotocol available; insufficient informa-
tion to permit a judgement of low or high
risk
Other bias Unclear risk Baseline characteristics: balanced except for
mean birth weight
ITT analysis was used
Formal sample size calculations were per-
formed
Use of co-interventions: intercurrent ill-
nesses were managed according to local
community treatment guidelines
Compliance with treatment: no informa-
tion provided
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Mandel 1987
Methods Allocation: randomised (block-randomisation)
Design: parallel groups, double-blind, double-dummy
Participants Number: 518 children (474 included in analysis at 4 weeks)
Age (mean): unknown (range 7 months to 12 years)
Gender: 64% boys, 36% girls
Duration of OME prior at baseline (mean): unknown
Laterality of disease at baseline (%): 69% bilateral disease
Setting: secondary care, Children’s Hospital of Pittsburgh Otitis Media Research Center
Eligibility criteria:
1. Children aged 7 months to 12 years
2. Unilateral or bilateral OME documented by otoscopy, middle ear muscle reflex and
tympanometry
Exclusion criteria: congenital craniofacial malformations, systemic illness, history of
ENT surgery, structural middle ear abnormality, hearing loss not attributable to MEE,
severe upper airway obstruction, AOM, acute or chronic sinusitis, history of treatment
with sympathomimetic amines or antihistamines during the prior 30 days, history or
hypersensitivity to any form of penicillin
Interventions Intervention group: amoxicillin 40 mg/kg/day in 3 doses for 2 weeks plus placebo 4
times daily for 4 weeks; n = ? (n = 160 included in analysis)
Intervention group 2: amoxicillin 40 mg/kg/day in 3 doses for 2 weeks plus pseu-
doephedrine hydrochloride and chlorpheniramine maleate 1.0 and 0.09 mg/kg 4 times
daily for 4 weeks (decongestant-antihistamine); n = ? (n = 158 included in analysis)
Comparator group: placebo in 3 doses for 2 weeks plus placebo 4 times daily for 4
weeks; n = ? (n = 156 included in analysis)
Use of additional interventions: acute symptomatic episodes (fever, ear pain or both)
were treated with an antimicrobial agent other than amoxicillin for 10 days with the
originally assigned decongestant-antihistamine or its placebo
Outcomes Primary outcome: complete resolution of OME at 4 weeks based on otoscopy, middle
ear muscle reflex and tympanometry (type A, C1 or C2 tympanogram)
Secondary outcomes: complete resolution of OME at 2 weeks, partial or complete
resolution of OME at 4 weeks, AOM at 4 weeks, OME recurrences at 4 weeks and 3
months, adverse effects, hearing levels based on speech recognition thresholds
Funding sources The Otitis Media Research Center is supported by a grant from the National Institute
of Neurological and Communicative Disorders and Stroke, National Institute of Health
Declaration of interest No information provided
Notes Participants lost to follow-up total: 44/518 children (8%); no further information
provided
Risk of bias
Bias Authors’ judgement Support for judgement
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Mandel 1987 (Continued)
Random sequence generation (selection
bias)
Low risk Block-randomisation (n = 3) stratified by
24 subgroups
Allocation concealment (selection bias) Low risk Quote: “Within each subgroup, subjects
were randomly assigned in a double-blind
fashion (in blocks of three) to one of the
following three groups: ...”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind. Quote: “The amoxicillin
placebo was similar in appearance and
taste to the active medication… The corre-
sponding placebo was identical in appear-
ance and similar in taste to the active med-
ication (decongestant-antihistamine)”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double-blind. Primary outcome based on
objective tympanometry
Incomplete outcome data (attrition bias)
All outcomes
High risk Total of randomised children per subgroup
not reported
8% of children lost to follow-up
Selective reporting (reporting bias) Unclear risk Protocol not available; insufficient infor-
mation to permit a judgement of low or
high risk
Other bias High risk Baseline characteristics: balanced
Unclear whether they used ITT analysis
No formal sample size calculations were
performed
Use of co-interventions: additional antimi-
crobial treatment for AOM or other con-
ditions was given in 36 children (18 in the
control group), no other co-interventions
described
Compliance with treatment: information
on compliance provided; 77% to 91% of
children received at least 75% of the as-
signed medication
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Mandel 1991
Methods Allocation: randomised (block randomisation)
Design: parallel groups, double-blind
Participants Number: 331 children (310 included in analysis at 4 weeks)
Age (mean): unknown (range 7 months to 12 years)
Gender: 56% boys, 44% girls
Duration of OME prior at baseline (mean): unknown
Laterality of disease at baseline (%): 71% bilateral disease
Setting: secondary care, Children’s Hospital of Pittsburgh Otitis Media Research Center
Eligibility criteria:
1. Children aged 7 months to 12 years
2. Unilateral or bilateral OME documented by otoscopy, middle ear muscle reflex and
tympanometry
Exclusion criteria: congenital craniofacial malformations, systemic illness, history of
ENT surgery, structural middle ear abnormality, hearing loss not attributable to MEE,
severe upper airway obstruction, AOM, acute or chronic sinusitis, history of treatment
with sympathomimetic amines or antihistamines during the prior 30 days, history or
hypersensitivity to any form of penicillin
Interventions Intervention group: erythromycin-sulfisoxazole 50 and 150 mg/kg/day in 4 doses for
2 weeks; n = 84
Intervention group 2: cefaclor 40 mg/kg/day in 3 doses for 2 weeks; n = 83
Intervention group 3: amoxicillin 40 mg/kg/day in 3 doses for 2 weeks; n = 83
Comparator group: placebo either in 3 or 4 doses for 2 weeks; n = 81
Use of additional interventions: AOM episodes were treated with an antimicrobial
agent differing in colour from the participant’s originally assigned medication for 10
days
Outcomes Primary outcome: complete resolution of OME at 2 and 4 weeks based on otoscopy,
middle ear muscle reflex and tympanometry (type A, C1 or C2 tympanogram)
Secondary outcomes: partial or complete resolution of OME at 4 weeks, AOM at 2 and
4 weeks, OME recurrences at 16 weeks, adverse effects, hearing levels based on speech
recognition thresholds
Funding sources The study was supported in part by grants from the National Institute of Health, Eli
Lilly Company (supplied cefaclor) and Ross Laboratories (supplied erythromycin-sul-
fisoxazole)
Declaration of interest No information provided
Notes Participants lost to follow-up total: 21/331 children (6%)
Participants lost to follow-up in erythromycin-sulfisoxazole group: 4/84 children
(5%)
Participants lost to follow-up in cefaclor group: 5/83 children (6%)
Participants lost to follow-up in amoxicillin group: 6/83 children (7%)
Participants lost to follow-up in control group: 6/81 children (7%)
Participants lost to follow-up in combined antibiotic group: 15/250 children (6%)
Risk of bias
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Mandel 1991 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Block randomisation (n = 4) stratified by 6
subgroups
Allocation concealment (selection bias) Low risk Quote: “The medication assigned was un-
known to the study physician and to the
parent”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind. Quote: “... to receive a
placebo that was color-matched and sim-
ilar in taste to erythromycin-sulfisoxazole
(white), cefaclor (purple), or amoxicillin
(pink)…All assignedmedicationswere dis-
pensedwith parents and physicians blinded
as to their content.”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double-blind. Primary outcome based on
objective tympanometry
Incomplete outcome data (attrition bias)
All outcomes
Low risk 6% of children lost to follow-up
Selective reporting (reporting bias) Unclear risk Protocol not available; insufficient infor-
mation to permit a judgement of low or
high risk
Other bias Unclear risk Baseline characteristics: balanced
ITT analysis were used
Formal sample size calculations were per-
formed
Use of co-interventions: additional antimi-
crobial treatment for AOM was given in
35 children (10 in the control group); no
other co-interventions described
Compliance with treatment: information
on compliance provided; 92% to 96% of
children received the assigned medication
Marchisio 1998
Methods Allocation: randomised
Design: parallel groups, investigator-blinded
Participants Number: 120 children (111 included in analysis at 4 and 8 weeks)
Age (mean): unknown (range 5 to 7 years)
Gender: 58% boys, 42% girls
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Marchisio 1998 (Continued)
Duration of OME prior at baseline (mean): unknown; OME had to last for at least
12 weeks
Laterality of disease at baseline (%): 70% bilateral disease
Setting: community, 11 primary schools in different regions of Italy
Eligibility criteria:
1. Children aged 7 months to 12 years
2. Unilateral or bilateral OME for 12weeks documented by otoscopy and tympanometry
(type B tympanogram)
Exclusion criteria: hypersensitivity to a beta-lactam drug, antibiotic therapy in prior
4 weeks, concomitant upper respiratory infection that would preclude evaluation of
response to study medication
Interventions Intervention group: ceftibuten (cephalosporin) 9 mg/kg/day in 1 dose for 2 weeks; n =
58
Comparator group: no treatment (only nasal saline drops were allowed); n = 62
Use of additional interventions: not described
Outcomes Primary outcome: complete resolution of OME at 4 and 8 weeks based on otoscopy
and tympanometry (type A, C1 or C2 tympanogram)
Secondary outcomes: partial or complete resolution of OME at 4 and 8 weeks, adverse
effects
Funding sources The study was supported in part by Recordati SpA, Italy, which supplied ceftibuten
Declaration of interest No information provided
Notes Participants lost to follow-up total: 9/120 children (8%)
Participants lost to follow-up in ceftibuten group: 6/58 children (10%)
Participants lost to follow-up in control group: 3/62 children (5%)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “Local randomisation list”. No fur-
ther information provided
Allocation concealment (selection bias) Unclear risk Method not described
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Investigator-blinded; parents were aware of
the allocated treatment, investigators were
blinded to treatment assignment during
follow-up
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Investigator-blinded. Primary outcome
based on objective tympanometry
49Antibiotics for otitis media with effusion in children (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Marchisio 1998 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Due to protocol violations 9 children were
excluded from analysis. As far as outcome is
concerned, all children returned for sched-
uled follow-up visits
8% of children lost to follow-up
Selective reporting (reporting bias) Unclear risk Noprotocol available; insufficient informa-
tion to permit a judgement of low or high
risk
Other bias Unclear risk Baseline characteristics: balanced
Unclear whether they used ITT analysis
No formal sample size calculations were
performed
Use of co-interventions: only nasal saline
drops were allowed in the control group
Compliance with treatment: no informa-
tion provided
Marks 1981
Methods Allocation: randomised
Design: parallel groups, double-blind
Participants Number: 59 children (51 included in analysis at 4 to 6 weeks)
Age (mean): 6.2 years
Gender: 56% boys, 44% girls
Duration of OME prior at baseline (mean): unknown
Laterality of disease at baseline (%): unknown
Setting: unclear, London, UK
Eligibility criteria:
1. Children below 12 years of age
2. Unilateral or bilateral OME documented by otoscopy, audiometry (audiogram had
to show a 15 dB air/bone gap or greater) and tympanometry (type B tympanogram)
Exclusion criteria: none
Interventions Intervention group: TMP-SMX 5 ml 3 times daily for 4 weeks; n = 30
Comparator group:Dimotapp elixir (decongestant); n = 29
Use of additional interventions: not described
Outcomes Primary outcome: partial or complete resolution of OME at 4 to 6 weeks based on
otoscopy, audiometry (audiogram had to show a 15 dB air/bone gap or greater) and
tympanometry (type A, C1 or C2 tympanogram)
Funding sources No information provided
Declaration of interest No information provided
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Marks 1981 (Continued)
Notes Participants lost to follow-up total: 8/59 children (14%)
Participants lost to follow-up in cotrimoxazole group: 5/30 children (17%)
Participants lost to follow-up in control group: 3/29 children (10%)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method not described
Allocation concealment (selection bias) High risk Alternative allocation
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Stated to be double-blinded, but insuffi-
cient information provided on how blind-
ing was ensured
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Stated to be double-blinded. Primary out-
come based on objective tympanometry
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 14% of children lost to follow-up
Selective reporting (reporting bias) Unclear risk Noprotocol available; insufficient informa-
tion to permit a judgement of low or high
risk
Other bias Unclear risk Baseline characteristics: balanced
Did not perform ITT analysis
No formal sample size calculations were
performed
Use of co-interventions: not allowed
Compliance with treatment: no informa-
tion provided
Moller 1990
Methods Allocation: randomised
Design: parallel groups, double-blind
Participants Number: 147 children (141 included in analysis at 4 weeks)
Age (median): 5 years
Gender: 56% boys, 44% girls
Duration of OME prior at baseline (mean): unknown; OME had to last for at least
12 weeks
Laterality of disease at baseline (%): 100% bilateral disease
Setting: secondary care, Bergen, Norway
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Moller 1990 (Continued)
Eligibility criteria:
1. Children aged 1 to 15 years
2. Bilateral OME for at least 3 months documented by otomicroscopy, pure tone hearing
tests and tympanometry (type B tympanogram)
3. Candidates for ventilation tubes
Exclusion criteria: no AOM in prior 3 months, no antibiotic use in prior 3 months, no
obstructive adenoid tissue
Interventions Intervention group: erythromycin 50 mg/kg/day divided into 2 doses for 14 days; n =
? (n = 69 included in analysis)
Comparator group: placebo for 14 days; n = ? (n = 72 included in analysis)
Use of additional interventions: not described
Outcomes Primary outcome: complete resolution of OME at 4 weeks based on otomicroscopy,
pure tone hearing tests and tympanometry (type A, C1 or C2 tympanogram)
Secondary outcome: adverse effects
Funding sources No information provided
Declaration of interest No information provided
Notes Participants lost to follow-up total: 6/147 children (4%)
Quote: “six patients were unable to continue due to intercurrent disease or an unwill-
ingness to participate”. No further information provided
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method not described
Allocation concealment (selection bias) Unclear risk Method not described
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “The drugs were administered dou-
ble blind… dispensed by the hospital phar-
macist in two daily doses…”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double-blind. Primary outcome objective
tympanometry.
Incomplete outcome data (attrition bias)
All outcomes
High risk Total of randomised children per subgroup
not reported
4% of children lost to follow-up
Selective reporting (reporting bias) Unclear risk Protocol not available; insufficient infor-
mation to permit a judgement of low or
high risk
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Moller 1990 (Continued)
Other bias Unclear risk Baseline characteristics: no information
provided
Unclear whether they used ITT analysis
No formal sample size calculations were
performed
Use of co-interventions: no information
provided
Compliance with treatment: no informa-
tion provided
Otten 1990
Methods Allocation: randomised
Design: parallel groups, double-blind
Participants Number: 141 children (139 included in analysis at 6, 12 and 26 weeks)
Age (mean): unknown (range 3 to 10 years)
Gender: 57% boys, 43% girls
Duration of OME prior at baseline (mean): unknown
Laterality of disease at baseline (%): unknown
Setting: secondary care, Leiden, The Netherlands
Eligibility criteria:
1. Children aged 3 to 10 years
2. Unilateral or bilateral OME documented by pneumatic otoscopy, otomicroscopy and
tympanometry (type B or C2 tympanogram)
3. Chronic rhinosinusitis: purulent rhinitis for at least 3 months and radiological abnor-
malities of the maxillary sinus in the form of opacity or mucosal swelling
Exclusion criteria: signs of chronic lower respiratory tract infections, nasal allergies,
allergies to amoxicillin, totally obstructive adenoids, Down syndrome
Interventions Intervention group: amoxicillin 250 mg 3 times daily for 10 days + xylometazoline
hydrochloride nose drops 0.5%; n = 38
Intervention group 2: amoxicillin 250 mg 3 times daily for 10 days + xylometazoline
hydrochloride nose drops 0.5% + drainage of the maxillary sinus; n = 35
Intervention group 3: placebo 3 times daily for 10 days + physiological saline nasal
drops 0.5% + drainage of the maxillary sinus; n = 30
Comparator group: placebo 3 times daily for 10 days + physiological saline nasal drops
0.5%; n = 38
Use of additional interventions: in cases in which the upper respiratory tract infection
or OME was not cured within 12 weeks or parents did not wish their children to remain
in the study supplementary treatment could be given
Outcomes Primary outcome: complete resolution of OME at 26 weeks based on pneumatic oto-
scopy, otomicroscopy and tympanometry (type A or C1 tympanogram)
Funding sources No information provided
Declaration of interest No information provided
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Otten 1990 (Continued)
Notes Participants lost to follow-up total: 2/141 children (1%)
Participants lost to follow-up in antibiotic group: 1/73 children (1%)
Participants lost to follow-up in control group: 1/68 children (1%)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method not described
Allocation concealment (selection bias) Unclear risk Method not described
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “The medication could be given
on a double-blind basis; the drainage could
not”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double-blind. Primary outcome based on
objective tympanometry
Incomplete outcome data (attrition bias)
All outcomes
Low risk 1% of children lost to follow-up
Selective reporting (reporting bias) Unclear risk Noprotocol available; insufficient informa-
tion to permit a judgement of low or high
risk
Other bias High risk Baseline characteristics: balanced
Unclear whether they used ITT analysis
No formal sample size calculations were
performed
Use of co-interventions: possibility of sup-
plemental treatment when OME or an
upper respiratory tract infection was still
present after 12 weeks
Compliance with treatment: no informa-
tion provided
Podoshin 1990
Methods Allocation: randomised
Design: parallel groups, double-blind
Participants Number: 150 children (136 included in analysis at 8 weeks)
Age (mean): 6.8 years
Gender: 53% boys, 47% girls
Duration of OME prior at baseline (mean): unknown; OME had to last for at least 8
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Podoshin 1990 (Continued)
weeks
Laterality of disease at baseline (%): unknown
Setting: secondary care, Haifa, Israel
Eligibility criteria:
1. Children aged 3 to 8 years
2. Unilateral or bilateral OME for at least 2 months documented by pneumatic otoscopy
and tympanometry (type B tympanogram)
Exclusion criteria: signs of fluid lines, air bubbles or yellow fluid
Interventions Intervention group: amoxicillin 50 mg/kg/day + placebo for 2 weeks; n = 50
Intervention group 2: amoxicillin 50 mg/kg/day + prednisone 1 mg/kg/day (dosage
was reduced by 5 mg every 2 days) for 2 weeks; n = 50; this group was not included in our
analyses
Comparator group: placebo + placebo; n = 50
Use of additional interventions: not described
Outcomes Primary outcome: complete resolution of OME at 2 months based on pneumatic
otoscopy and tympanometry (type A tympanogram)
Secondary outcome: improvement of OME at 2 months based on pneumatic otoscopy
and tympanometry (type C1 or C2 tympanogram)
Funding sources No information provided
Declaration of interest No information provided
Notes Participants lost to follow-up total: 14/150 children (9%)
Participants lost to follow-up in antibiotic group: 1/50 children (2%)
Participants lost to follow-up in control group: 13/50 children (26%)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method not described
Allocation concealment (selection bias) Unclear risk Method not described
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind fashion.Quote: “The amoxi-
cillin, prednisone, and placebo…was given
to the treating physician”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double-blind. Primary outcome based on
objective tympanometry
Incomplete outcome data (attrition bias)
All outcomes
High risk 9% of children lost to follow-up; 2% in an-
tibiotic group versus 26% in placebo group
55Antibiotics for otitis media with effusion in children (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Podoshin 1990 (Continued)
Selective reporting (reporting bias) Unclear risk Noprotocol available; insufficient informa-
tion to permit a judgement of low or high
risk
Other bias Unclear risk Baseline characteristics: balanced
ITT analysis were used
No formal sample size calculations were
performed
Use of co-interventions: no information
provided
Compliance with treatment: no informa-
tion provided
Principi 1989
Methods Allocation: randomised
Design: parallel groups, double-blind
Participants Number: 100 children (93 included in analysis at 6 months)
Age (mean): unknown (range 9 months to 5 years)
Gender: 55% boys, 45% girls
Duration of OME prior at baseline (mean): unknown
Laterality of disease at baseline (%): 81% bilateral disease
Setting: tertiary care, Milan, Italy
Eligibility criteria:
1. Children aged 9 months to 5 years
2. Unilateral or bilateral OME documented by otoscopy and tympanometry (type B
tympanogram)
3. 3 or more AOM episodes in the prior 6 months as confirmed by otoscopy and
tympanometry with the last episode occurring between 15 days and 2 months prior to
enrolment
Exclusion criteria: cleft palate, Down syndrome, immunodeficiency, history or allergic
reactions to any of the study drugs
Interventions Intervention group: amoxicillin 20 mg/kg/day once daily for 6 months; n = 34
Intervention group 2: TMP-SMX 12 mg/kg/day once daily for 6 months; n = 33
Comparator group: placebo once daily for 6 months; n = 33
Use of additional interventions: AOM episodes were treated with cefaclor (prophylaxis
was discontinued) for 10 days. If acute signs persisted tympanocentesis was performed
and another antimicrobial drug was prescribed based on the sensitivity of the isolated
pathogen. If another infectious disease requiring antibiotic treatment occurred, prophy-
laxis was stopped and the more appropriate treatment instituted. A child was discharged
from the study in case of 2 AOM episodes within a 2-month period
Outcomes Primary outcome: complete resolution of OME at 6 months based on otoscopy and
tympanometry (type A, C1 or C2 tympanogram)
Secondary outcome: adverse effects and AOM at 6 months
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Principi 1989 (Continued)
Funding sources No information provided
Declaration of interest No information provided
Notes Participants lost to follow-up total: 7/100 children (7%)
Participants lost to follow-up in antibiotic group: 3/67 children (4%)
Participants lost to follow-up in control group: 4/33 children (12%)
1 child in each antibiotic group had no OME at randomisation
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method not described
Allocation concealment (selection bias) Unclear risk Method not described
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “... the placebo was similar in ap-
pearance to one of the active drugs.”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double-blind. Primary outcome based on
objective tympanometry
Incomplete outcome data (attrition bias)
All outcomes
High risk 7% of children lost to follow-up; 4% in an-
tibiotic group versus 12% in placebo group
Selective reporting (reporting bias) Unclear risk Noprotocol available; insufficient informa-
tion to permit a judgement of low or high
risk
Other bias High risk Baseline characteristics: balanced
Did not perform ITT analysis
No formal sample size calculations were
performed
Use of co-interventions: antibiotic treat-
ment in case of AOM episodes or other in-
fectious disease requiring antibiotic treat-
ment
Compliance with treatment: compliance
with medication was good in 97% (32/33)
of children with amoxicillin, in 94% (31/
33) of those receiving sulfamethoxazole and
trimethoprim, and in 97% (29/30) of chil-
dren who received placebo
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Safak 2001
Methods Allocation: randomised
Design: parallel groups, double-blind
Participants Number: 90 children (90 included in analysis)
Age (mean): 5.8 years
Gender: 49% boys, 51% girls
Duration of OME prior at baseline (mean): unknown; OME had to last for at least 4
weeks
Laterality of disease at baseline (%): unknown
Setting: secondary care, Ankara, Turkey
Eligibility criteria:
1. Children aged 2 to 13 years
2. Unilateral or bilateral OME for at least 4 weeks documented by pneumatic otoscopy
and tympanometry (type B tympanogram)
3. No previous medication in prior 3 months
Exclusion criteria: severe septal deviation, totally obstructive adenoid hypertrophy, al-
lergic signs
Interventions Intervention group: azithromycin 10 mg/kg/day once daily for 3 days, repeated for up
to 12 weeks; n = 30
Intervention group 2: azithromycin 10 mg/kg/day once daily for 3 days for the first
week; this dose was then repeated for 1 day a week for up to 12 weeks; n = 30
Comparator group: pseudoephedrine hydrochloride (decongestant) 4 mg/kg 3 daily
for 12 weeks; n = 30
Use of additional interventions: not described
Outcomes Primary outcome: complete resolution of OME at 1, 2 and 3 months based on pneu-
matic otoscopy and tympanometry (type A tympanogram)
Secondary outcome: improvement of OME at 1, 2 and 3 months based on pneumatic
otoscopy and tympanometry (type C1 or C2 tympanogram)
Funding sources No information provided
Declaration of interest No information provided
Notes Participants lost to follow-up total: 0/90 children (0%)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method not described
Allocation concealment (selection bias) Unclear risk Method not described
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Stated to be double-blinded, but insuffi-
cient information provided on how blind-
ing was ensured
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Safak 2001 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Stated to be double-blinded. Primary out-
come based on objective tympanometry
Incomplete outcome data (attrition bias)
All outcomes
Low risk No children lost to follow-up
Selective reporting (reporting bias) Unclear risk Noprotocol available; insufficient informa-
tion to permit a judgement of low or high
risk
Other bias Unclear risk Baseline characteristics: balanced
Unclear whether they used ITT analysis
No formal sample size calculations were
performed
Use of co-interventions: no information
provided
Compliance with treatment: no informa-
tion provided
Schwartz 1982
Methods Allocation: randomised
Design: parallel groups, open-label
Participants Number: 69 children (64 included in analysis at 4 weeks)
Age (mean): 3.6 years
Gender: 60% boys, 40% girls
Duration of OME prior at baseline (mean): unknown
Laterality of disease at baseline (%): unknown
Setting: secondary care, Washington, USA
Eligibility criteria:
1. Persistent unilateral or bilateral OME documented by pneumatic otoscopy and tym-
panometry (type B tympanogram)
2. Recent AOM episode within 15 days of enrolment
3. Previous amoxicillin treatment for at least 10 days
Exclusion criteria: none described
Interventions Intervention group: TMP-SMX 4 mg/kg/day once daily for 2 weeks; n = 33
Comparator group: no treatment; n = 36
Use of additional interventions: neither decongestants nor antihistamines were pre-
scribed
Outcomes Primary outcome: complete resolution of OME at 2, 4, 6 weeks and 3 months based
on pneumatic otoscopy and tympanometry (type A, C1 or C2 tympanogram)
Secondary outcome: AOM at 2 and 4 weeks
Funding sources No information provided
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Schwartz 1982 (Continued)
Declaration of interest No information provided
Notes Participants lost to follow-up total: 5/69 children (7%)
Participants lost to follow-up in antibiotic group: 3/33 children (9%)
Participants lost to follow-up in control group: 2/36 children (6%)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Alternative allocation
Allocation concealment (selection bias) High risk Alternative allocation
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Not blinded. Primary outcome based on
objective tympanometry
Incomplete outcome data (attrition bias)
All outcomes
Low risk 7% of children lost to follow-up
Selective reporting (reporting bias) Unclear risk Noprotocol available; insufficient informa-
tion to permit a judgement of low or high
risk
Other bias Unclear risk Baseline characteristics: balanced, except
for gender
Did not perform ITT analysis
No formal sample size calculations were
performed
Use of co-interventions: no other medica-
tion prescribed
Compliance with treatment: not tested
Thomsen 1989
Methods Allocation: randomised
Design: parallel groups, double-blind
Participants Number: 264 children (221 included in analysis)
Age (mean): unknown (range 1 to 10 years)
Gender: 52% boys, 48% girls
Duration of OME prior at baseline (mean): unknown; OME had to last for at least
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Thomsen 1989 (Continued)
12 weeks
Laterality of disease at baseline (%): unknown
Setting: secondary care, Hellerup, Denmark
Eligibility criteria:
1. Children aged 1 to 10 years
2. Unilateral or bilateral OME for at least 3months documented by tympanometry (type
B or C2 tympanogram)
In children with bilateral disease, a ventilation tube was inserted in the right ear whereas
the left ear was included in the study
Exclusion criteria: allergy to penicillin
Interventions Intervention group: amoxicillin-clavulanic acid 25/6.25 mg/ml for 4 weeks (1 to 5
years: 5 ml 3 times daily; 6 to 10: 7.5 ml 3 times daily); n = 131
Comparator group: placebo for 4 weeks; n = 133
Use of additional interventions: no concomitant medications other than antipyretic
or analgesic were allowed during the treatment period
Outcomes Primary outcome: complete resolution of OME at 4 weeks based on tympanometry
(type A or C1 tympanogram)
Secondary outcome: adverse effects at 4 weeks, time with abnormal tympanogram at
12 months
Funding sources No information provided
Declaration of interest No information provided
Notes Participants lost to follow-up total: 43/264 children (16%)
Participants lost to follow-up in antibiotic group: 22/131 children (17%) as described
in text of manuscript; 20/131 (15%) as extracted from Table 6
Participants lost to follow-up in control group: 21/133 children (16%) as described
in text of manuscript; 23/131 (17%) as extracted from Table 6
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method not described
Allocation concealment (selection bias) Unclear risk Method not described
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “All medications were dispensed in
a double-blind fashion”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double-blind. Primary outcome based on
objective tympanometry
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Thomsen 1989 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
High risk 16% of children lost to follow-up; discrep-
ancies between numbers provided in text
and table
Selective reporting (reporting bias) Unclear risk Noprotocol available; insufficient informa-
tion to permit a judgement of low or high
risk
Other bias Unclear risk Baseline characteristics: balanced
Did not perform ITT analysis
No formal sample size calculations were
performed
Use of co-interventions: no concomitant
medications other than antipyretic or anal-
gesic were allowed during the treatment pe-
riod
Compliance with treatment: parental
records and bottle method were used, but
actual compliance rates were not reported
van Balen 1996
Methods Allocation: randomised
Design: parallel groups, double-blind
Participants Number: 162 children (153 included in analysis)
Age (mean): unknown (range 6 months to 6 years)
Gender: 52% boys, 48% girls
Duration of OME prior at baseline (mean): unknown; OME had to last for at least
12 weeks
Laterality of disease at baseline (%): 100% bilateral disease
Setting: primary care, Utrecht, the Netherlands
Eligibility criteria:
1. Children aged 6 months to 6 years
2. Bilateral OME for at least 3 months documented by otoscopy and tympanometry
(type B or C2 tympanogram)
Exclusion criteria: antibiotic treatment in prior 4weeks, penicillin allergy, compromised
immunity, referral to an ENT surgeon at time of inclusion, craniofacial abnormalities,
Down syndrome, cystic fibrosis
Interventions Intervention group: amoxicillin-clavulanic acid 20/5 mg/kg divided into 3 daily doses
for 2 weeks + xylometazoline 0.25% nose drops (decongestant) 3 times daily; n = 82
Comparator group: placebo for 2 weeks + xylometazoline 0.25% nose drops (decon-
gestant) 3 times daily; n = 80
Use of additional interventions: general practitioners were free in their choice of treat-
ment at the 2-week follow-up visit
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van Balen 1996 (Continued)
Outcomes Primary outcome: complete resolution of OME at 2 weeks based on otoscopy and
tympanometry (type A or C1 tympanogram)
Secondary outcome: partial or complete resolution of OME at 2 weeks, adverse effects
at 2 weeks
Funding sources SmithKline Beecham supplied the study drug (Augmentin) and placebo and ZymaGeigy
the nose drops (Otrivin). The study was supported by the Netherlands Organisation for
Scientific Research
Declaration of interest No information provided
Notes Participants lost to follow-up total: 9/162 children (6%)
Participants lost to follow-up in antibiotic group: 3/82 children (4%)
Participants lost to follow-up in control group: 6/80 children (8%)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computerised block randomisation (n = 4)
Allocation concealment (selection bias) Low risk Quote: “The suspensionswere dispensed to
participating general practitioners in a dou-
ble-blind fashion with computerised four-
block randomisation.”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “...placebo with same colour and
taste...”
Quote: “Throughout the study, doctor and
patient remained blinded.”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double-blind. Primary outcome based on
objective tympanometry
Incomplete outcome data (attrition bias)
All outcomes
Low risk 6% of children lost to follow-up
Selective reporting (reporting bias) Unclear risk Noprotocol available; insufficient informa-
tion to permit a judgement of low or high
risk
Other bias High risk Baseline characteristics: significantly more
males in the placebo group, which also
showed to be a significant prognostic factor
in this study
Did not perform ITT analysis
No formal sample size calculations were
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van Balen 1996 (Continued)
performed
Use of co-interventions: no concomitant
medications other than antipyretic or anal-
gesic were allowed during the treatment pe-
riod
Compliance with treatment: measured by
examination of the diaries and measure-
ment of suspension that remained in the
bottle, 90% of all patients took the medi-
cation for at least 10 days
AOM: acute otitis media
ENT: ear, nose and throat
ITT: intention-to-treat
MEE: middle ear effusion
OME: otitis media with effusion
RCT: randomised controlled trial
Rx: prescription
TMP-SMX: trimethoprim-sulfamethoxazole
Tx: treatment
VT: ventilation tube
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Balle 1998 INTERVENTIONS
One antibiotic was compared with another antibiotic (amoxicillin/clavulanic acid versus penicillin V)
Berman 1987 INTERVENTIONS
Antibiotics were compared with antibiotics in combination with corticosteroids (sulfamethoxazole with and
without prednisone)
Berman 1990 INTERVENTIONS
Antibiotics were compared with antibiotics in combination with corticosteroids (TMP-SMXwith and without
prednisone)
Bojanovic 1999 Only published in abstract form - no full-text publication
Cantekin 1991 Reanalysis of data originally published by Mandel and co-workers (Mandel 1987)
Chan 1988 INTERVENTIONS
One antibiotic was comparedwith another antibiotic (amoxicillin/clavulanic acid versus amoxicillin trihydrate)
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(Continued)
Combs 2004 PARTICIPANTS
Children were randomised on the basis of AOM; not all children were diagnosed with OME at the time of
randomisation
Donaldson 1990 INTERVENTIONS
One antibiotic (cefaclor) was used in all groups (different dosage)
Eiden 1997 ALLOCATION
Not a randomised controlled trial
Ernstson 1985a ALLOCATION
Not a randomised controlled trial
Fontanel 1998 ALLOCATION
Not a randomised controlled trial
Fujita 1994 PARTICIPANTS
Adults were also included (participants aged 10 to 20 years)
Gates 1986 ALLOCATION
Not a randomised controlled trial
Goodey 1975 ANALYSIS
Ears instead of patients were used as the unit of analysis
Heary 1990 Only published in abstract form - no full-text publication
Hong 2014 ALLOCATION
Not a randomised controlled trial
Howie 1971 PARTICIPANTS
Children were randomised on the basis of otitis media in general; not all children were diagnosed with OME
at the time of randomisation
Hozawa 2001 ALLOCATION
Not a randomised controlled trial
Karlidag 2002 ANALYSIS
Ears instead of patients were used as the unit of analysis
Mandel 1996 INTERVENTIONS
One antibiotic was compared with another antibiotic (ceftibuten versus amoxicillin)
Mandel 2002 INTERVENTIONS
Antibiotics were compared with antibiotics in combination with corticosteroids (amoxicillin with or without
prednisolone)
Margas 2004 Only published in abstract form - no full-text publication
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(Continued)
Mel-Hennawi 2015 INTERVENTIONS
Two antibiotics were compared with another antibiotic (clarithromycin, metronidazole (and lansoprazole)
versus amoxicillin/clavulanic acid)
Nsouli 2015 INTERVENTIONS
One antibiotic was compared with another antibiotic (clarithromycin versus amoxicillin/clavulanic acid)
Ortega 2005 INTERVENTIONS
Antibiotics were compared with antibiotics in combination with AM3 (immunoferon)
Ozmen 2010 ALLOCATION
Not a randomised controlled trial
Pestalozza 1992 PARTICIPANTS
Children were randomised on the basis of otitis media in general; not all children were diagnosed with OME
at the time of randomisation
Puhakka 1985 PARTICIPANTS
Diagnosis of OME was made without performing tympanometry
Rosenfeld 1995 ALLOCATION
Not a randomised controlled trial
Roydhouse 1991 ALLOCATION
Not a randomised controlled trial
Schloss 1988 Only published in abstract form - no full-text publication
Schwartz 1980 INTERVENTIONS
Antibiotics were comparedwith antibiotics in combinationwith corticosteroids (sulfisoxazole with andwithout
corticosteroids)
Schwartz 1982a PARTICIPANTS
All otitis-prone children were included; just a small number of children hadOME at the time of randomisation
Sundberg 1984 ALLOCATION
Not a randomised controlled trial
Tapiainen 2014 PARTICIPANTS
Children were randomised on the basis of AOM (and not OME)
Thomsen 1997 INTERVENTIONS
One antibiotic was compared with another antibiotic (penicillin V versus amoxicillin/clavulanic acid)
Tracy 1998 INTERVENTIONS
Prophylactic antibiotics were compared with prophylactic antibiotics in combination with intranasal corticos-
teroids (amoxicillin 20 mg/kg twice a day with or without addition of intranasal corticosteroids)
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(Continued)
Unlu 2005 Only published in abstract form - no full-text publication
Varsano 1985 ANALYSIS
Double-blind, cross-over trial; we were not able to separate the effect of the intervention of interest as the
results were only reported after treatment with both sulfisoxazole and placebo
Venekamp 2014 ALLOCATION
Not a randomised controlled trial
Yin 2002 INTERVENTIONS
One antibiotic was compared with another antibiotic (cefaclor versus roxithromycin)
Zocconi 1994 ALLOCATION
Not a randomised controlled trial
AOM: acute otitis media
OME: otitis media with effusion
Rx: prescription
TMP-SMX: trimethoprim-sulfamethoxazole
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D A T A A N D A N A L Y S E S
Comparison 1. Antibiotics versus placebo, no treatment or therapy of unproven effectiveness
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Complete resolution of OME at
2 to 3 months
6 484 Risk Ratio (M-H, Fixed, 95% CI) 2.00 [1.58, 2.53]
2 Adverse effects 5 742 Risk Ratio (M-H, Fixed, 95% CI) 2.15 [1.29, 3.60]
3 Complete resolution of OME at
2 to 4 weeks
14 2091 Risk Ratio (M-H, Random, 95% CI) 1.98 [1.47, 2.67]
4 Complete resolution of OME at
more than 6 months
5 606 Risk Ratio (M-H, Fixed, 95% CI) 1.75 [1.41, 2.18]
5 Complete resolution of OME
at end of treatment (10 to 14
days)
6 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
5.1 Duration of OME prior
to study entry < 3 months
4 885 Risk Ratio (M-H, Fixed, 95% CI) 1.83 [1.38, 2.44]
5.2 Duration of OME prior
to study entry ≥ 3 months
2 244 Risk Ratio (M-H, Fixed, 95% CI) 4.03 [2.13, 7.61]
6 Complete resolution of OME at
end of treatment (4 weeks)
4 479 Risk Ratio (IV, Random, 95% CI) 3.28 [1.37, 7.87]
7 Complete resolution of OME at
end of treatment (3 months)
2 150 Risk Ratio (M-H, Fixed, 95% CI) 2.10 [1.39, 3.17]
8 Complete resolution of OME at
end of treatment (6 months)
2 196 Risk Ratio (M-H, Random, 95% CI) 2.81 [0.29, 27.50]
9 Insertion of ventilation tubes 2 121 Risk Ratio (M-H, Fixed, 95% CI) 0.90 [0.46, 1.78]
10 Tympanic membrane sequelae 1 103 Risk Ratio (M-H, Fixed, 95% CI) 0.42 [0.18, 1.01]
11 AOM within 4 to 8 weeks 5 1086 Risk Ratio (M-H, Fixed, 95% CI) 0.60 [0.42, 0.85]
12 AOM within 6 months 2 199 Risk Ratio (IV, Fixed, 95% CI) 0.56 [0.40, 0.80]
Comparison 2. Sensitivity analysis - Antibiotics versus placebo, no treatment or therapy of unproven effectiveness
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Complete resolution of OME at
2 to 3 months
4 334 Risk Ratio (M-H, Fixed, 95% CI) 1.92 [1.51, 2.44]
2 Adverse effects 3 337 Risk Ratio (M-H, Fixed, 95% CI) 1.97 [1.16, 3.35]
3 Complete resolution of OME at
2 to 4 weeks
9 1147 Risk Ratio (M-H, Random, 95% CI) 2.58 [1.60, 4.17]
4 Complete resolution of OME at
more than 6 months
2 244 Risk Ratio (M-H, Fixed, 95% CI) 2.13 [1.30, 3.50]
5 Complete resolution of OME
at end of treatment (10 to 14
days)
4 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
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5.1 Duration of OME prior
to study entry < 3 month
2 356 Risk Ratio (M-H, Fixed, 95% CI) 1.85 [1.07, 3.21]
5.2 Duration of OME prior
to study entry ≥ 3 months
2 244 Risk Ratio (M-H, Fixed, 95% CI) 4.03 [2.13, 7.61]
6 Complete resolution of OME at
end of treatment (4 weeks)
2 219 Risk Ratio (M-H, Fixed, 95% CI) 9.19 [4.29, 19.70]
7 AOM within 4 to 8 weeks 2 510 Risk Ratio (M-H, Fixed, 95% CI) 0.70 [0.37, 1.31]
Analysis 1.1. Comparison 1 Antibiotics versus placebo, no treatment or therapy of unproven effectiveness,
Outcome 1 Complete resolution of OME at 2 to 3 months.
Review: Antibiotics for otitis media with effusion in children
Comparison: 1 Antibiotics versus placebo, no treatment or therapy of unproven effectiveness
Outcome: 1 Complete resolution of OME at 2 to 3 months
Study or subgroup Antibiotics Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ardehali 2008 12/30 3/30 5.0 % 4.00 [ 1.25, 12.75 ]
Chen 2013 33/36 23/37 38.1 % 1.47 [ 1.13, 1.93 ]
Marchisio 1998 19/52 11/59 17.3 % 1.96 [ 1.03, 3.72 ]
Podoshin 1990 20/49 5/37 9.6 % 3.02 [ 1.25, 7.30 ]
Safak 2001 51/60 12/30 26.9 % 2.13 [ 1.35, 3.34 ]
Schwartz 1982 2/30 2/34 3.1 % 1.13 [ 0.17, 7.56 ]
Total (95% CI) 257 227 100.0 % 2.00 [ 1.58, 2.53 ]
Total events: 137 (Antibiotics), 56 (Control)
Heterogeneity: Chi2 = 7.49, df = 5 (P = 0.19); I2 =33%
Test for overall effect: Z = 5.77 (P < 0.00001)
Test for subgroup differences: Not applicable
0.05 0.2 1 5 20
Favours control Favours antibiotics
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Analysis 1.2. Comparison 1 Antibiotics versus placebo, no treatment or therapy of unproven effectiveness,
Outcome 2 Adverse effects.
Review: Antibiotics for otitis media with effusion in children
Comparison: 1 Antibiotics versus placebo, no treatment or therapy of unproven effectiveness
Outcome: 2 Adverse effects
Study or subgroup Antibiotics Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Hemlin 1997 6/61 0/20 4.4 % 4.40 [ 0.26, 74.88 ]
Marchisio 1998 0/52 0/59 Not estimable
Moller 1990 0/69 0/72 Not estimable
Thomsen 1989 5/131 1/133 5.8 % 5.08 [ 0.60, 42.86 ]
van Balen 1996 29/74 15/71 89.8 % 1.85 [ 1.09, 3.16 ]
Total (95% CI) 387 355 100.0 % 2.15 [ 1.29, 3.60 ]
Total events: 40 (Antibiotics), 16 (Control)
Heterogeneity: Chi2 = 1.17, df = 2 (P = 0.56); I2 =0.0%
Test for overall effect: Z = 2.93 (P = 0.0034)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours antibiotics Favours control
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Analysis 1.3. Comparison 1 Antibiotics versus placebo, no treatment or therapy of unproven effectiveness,
Outcome 3 Complete resolution of OME at 2 to 4 weeks.
Review: Antibiotics for otitis media with effusion in children
Comparison: 1 Antibiotics versus placebo, no treatment or therapy of unproven effectiveness
Outcome: 3 Complete resolution of OME at 2 to 4 weeks
Study or subgroup Antibiotics Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Moller 1990 12/69 19/72 7.6 % 0.66 [ 0.35, 1.25 ]
Mandel 1991 69/235 20/75 9.6 % 1.10 [ 0.72, 1.68 ]
Schwartz 1982 19/33 15/36 9.0 % 1.38 [ 0.85, 2.24 ]
Corwin 1986 33/66 22/65 9.6 % 1.48 [ 0.97, 2.24 ]
Giebink 1990 10/20 6/19 6.4 % 1.58 [ 0.72, 3.50 ]
Safak 2001 52/60 14/30 9.8 % 1.86 [ 1.25, 2.76 ]
Thomsen 1989 69/111 34/110 10.5 % 2.01 [ 1.47, 2.76 ]
Mandel 1987 96/318 22/156 9.6 % 2.14 [ 1.40, 3.26 ]
Marchisio 1998 15/52 7/59 6.3 % 2.43 [ 1.08, 5.50 ]
Daly 1991 5/21 2/21 2.9 % 2.50 [ 0.54, 11.48 ]
van Balen 1996 18/79 5/74 5.4 % 3.37 [ 1.32, 8.62 ]
Ernstson 1985 24/46 5/45 5.9 % 4.70 [ 1.96, 11.22 ]
Healy 1984 56/96 6/93 6.4 % 9.04 [ 4.09, 19.97 ]
de Castro 1982 5/15 0/15 1.0 % 11.00 [ 0.66, 182.87 ]
Total (95% CI) 1221 870 100.0 % 1.98 [ 1.47, 2.67 ]
Total events: 483 (Antibiotics), 177 (Control)
Heterogeneity: Tau2 = 0.19; Chi2 = 44.27, df = 13 (P = 0.00003); I2 =71%
Test for overall effect: Z = 4.52 (P < 0.00001)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours control Favours antibiotics
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Analysis 1.4. Comparison 1 Antibiotics versus placebo, no treatment or therapy of unproven effectiveness,
Outcome 4 Complete resolution of OME at more than 6 months.
Review: Antibiotics for otitis media with effusion in children
Comparison: 1 Antibiotics versus placebo, no treatment or therapy of unproven effectiveness
Outcome: 4 Complete resolution of OME at more than 6 months
Study or subgroup Antibiotics Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Choung 2008 14/31 8/17 13.2 % 0.96 [ 0.51, 1.81 ]
Leach 2008 6/52 0/51 0.6 % 12.75 [ 0.74, 220.70 ]
Otten 1990 31/73 16/68 21.2 % 1.80 [ 1.09, 2.99 ]
Principi 1989 35/64 12/29 21.2 % 1.32 [ 0.81, 2.15 ]
Thomsen 1989 69/111 34/110 43.7 % 2.01 [ 1.47, 2.76 ]
Total (95% CI) 331 275 100.0 % 1.75 [ 1.41, 2.18 ]
Total events: 155 (Antibiotics), 70 (Control)
Heterogeneity: Chi2 = 7.34, df = 4 (P = 0.12); I2 =45%
Test for overall effect: Z = 5.02 (P < 0.00001)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours control Favours antibiotics
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Analysis 1.5. Comparison 1 Antibiotics versus placebo, no treatment or therapy of unproven effectiveness,
Outcome 5 Complete resolution of OME at end of treatment (10 to 14 days).
Review: Antibiotics for otitis media with effusion in children
Comparison: 1 Antibiotics versus placebo, no treatment or therapy of unproven effectiveness
Outcome: 5 Complete resolution of OME at end of treatment (10 to 14 days)
Study or subgroup Antibiotics Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Duration of OME prior to study entry < 3 months
Daly 1991 5/21 2/21 3.3 % 2.50 [ 0.54, 11.48 ]
Mandel 1987 89/310 21/150 46.3 % 2.05 [ 1.33, 3.16 ]
Mandel 1991 59/236 11/78 27.0 % 1.77 [ 0.98, 3.20 ]
Schwartz 1982 19/33 15/36 23.4 % 1.38 [ 0.85, 2.24 ]
Subtotal (95% CI) 600 285 100.0 % 1.83 [ 1.38, 2.44 ]
Total events: 172 (Antibiotics), 49 (Control)
Heterogeneity: Chi2 = 1.73, df = 3 (P = 0.63); I2 =0.0%
Test for overall effect: Z = 4.13 (P = 0.000036)
2 Duration of OME prior to study entry≥ 3 months
Ernstson 1985 24/46 5/45 49.5 % 4.70 [ 1.96, 11.22 ]
van Balen 1996 18/79 5/74 50.5 % 3.37 [ 1.32, 8.62 ]
Subtotal (95% CI) 125 119 100.0 % 4.03 [ 2.13, 7.61 ]
Total events: 42 (Antibiotics), 10 (Control)
Heterogeneity: Chi2 = 0.26, df = 1 (P = 0.61); I2 =0.0%
Test for overall effect: Z = 4.29 (P = 0.000018)
Test for subgroup differences: Chi2 = 4.87, df = 1 (P = 0.03), I2 =79%
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Analysis 1.6. Comparison 1 Antibiotics versus placebo, no treatment or therapy of unproven effectiveness,
Outcome 6 Complete resolution of OME at end of treatment (4 weeks).
Review: Antibiotics for otitis media with effusion in children
Comparison: 1 Antibiotics versus placebo, no treatment or therapy of unproven effectiveness
Outcome: 6 Complete resolution of OME at end of treatment (4 weeks)
Study or subgroup Antibiotics Control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
de Castro 1982 5/15 0/15 7.7 % 11.00 [ 0.66, 182.87 ]
Giebink 1990 10/20 6/19 28.4 % 1.58 [ 0.72, 3.50 ]
Healy 1984 56/96 6/93 28.5 % 9.04 [ 4.09, 19.97 ]
Thomsen 1989 69/111 34/110 35.4 % 2.01 [ 1.47, 2.76 ]
Total (95% CI) 242 237 100.0 % 3.28 [ 1.37, 7.87 ]
Total events: 140 (Antibiotics), 46 (Control)
Heterogeneity: Tau2 = 0.54; Chi2 = 14.16, df = 3 (P = 0.003); I2 =79%
Test for overall effect: Z = 2.67 (P = 0.0077)
Test for subgroup differences: Not applicable
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74Antibiotics for otitis media with effusion in children (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.7. Comparison 1 Antibiotics versus placebo, no treatment or therapy of unproven effectiveness,
Outcome 7 Complete resolution of OME at end of treatment (3 months).
Review: Antibiotics for otitis media with effusion in children
Comparison: 1 Antibiotics versus placebo, no treatment or therapy of unproven effectiveness
Outcome: 7 Complete resolution of OME at end of treatment (3 months)
Study or subgroup Antibiotics Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ardehali 2008 12/30 3/30 14.8 % 4.00 [ 1.25, 12.75 ]
Safak 2001 46/60 13/30 85.2 % 1.77 [ 1.15, 2.73 ]
Total (95% CI) 90 60 100.0 % 2.10 [ 1.39, 3.17 ]
Total events: 58 (Antibiotics), 16 (Control)
Heterogeneity: Chi2 = 1.79, df = 1 (P = 0.18); I2 =44%
Test for overall effect: Z = 3.52 (P = 0.00043)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours control Favours antibiotics
Analysis 1.8. Comparison 1 Antibiotics versus placebo, no treatment or therapy of unproven effectiveness,
Outcome 8 Complete resolution of OME at end of treatment (6 months).
Review: Antibiotics for otitis media with effusion in children
Comparison: 1 Antibiotics versus placebo, no treatment or therapy of unproven effectiveness
Outcome: 8 Complete resolution of OME at end of treatment (6 months)
Study or subgroup Antibiotics Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Leach 2008 6/52 0/51 33.2 % 12.75 [ 0.74, 220.70 ]
Principi 1989 35/64 12/29 66.8 % 1.32 [ 0.81, 2.15 ]
Total (95% CI) 116 80 100.0 % 2.81 [ 0.29, 27.50 ]
Total events: 41 (Antibiotics), 12 (Control)
Heterogeneity: Tau2 = 1.97; Chi2 = 2.81, df = 1 (P = 0.09); I2 =64%
Test for overall effect: Z = 0.89 (P = 0.38)
Test for subgroup differences: Not applicable
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Analysis 1.9. Comparison 1 Antibiotics versus placebo, no treatment or therapy of unproven effectiveness,
Outcome 9 Insertion of ventilation tubes.
Review: Antibiotics for otitis media with effusion in children
Comparison: 1 Antibiotics versus placebo, no treatment or therapy of unproven effectiveness
Outcome: 9 Insertion of ventilation tubes
Study or subgroup Antibiotics Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Chen 2013 3/36 3/37 24.7 % 1.03 [ 0.22, 4.76 ]
Choung 2008 11/31 7/17 75.3 % 0.86 [ 0.41, 1.81 ]
Total (95% CI) 67 54 100.0 % 0.90 [ 0.46, 1.78 ]
Total events: 14 (Antibiotics), 10 (Control)
Heterogeneity: Chi2 = 0.04, df = 1 (P = 0.84); I2 =0.0%
Test for overall effect: Z = 0.30 (P = 0.77)
Test for subgroup differences: Not applicable
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Analysis 1.10. Comparison 1 Antibiotics versus placebo, no treatment or therapy of unproven effectiveness,
Outcome 10 Tympanic membrane sequelae.
Review: Antibiotics for otitis media with effusion in children
Comparison: 1 Antibiotics versus placebo, no treatment or therapy of unproven effectiveness
Outcome: 10 Tympanic membrane sequelae
Study or subgroup Antibiotics Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Leach 2008 6/52 14/51 100.0 % 0.42 [ 0.18, 1.01 ]
Total (95% CI) 52 51 100.0 % 0.42 [ 0.18, 1.01 ]
Total events: 6 (Antibiotics), 14 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.94 (P = 0.052)
Test for subgroup differences: Not applicable
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Analysis 1.11. Comparison 1 Antibiotics versus placebo, no treatment or therapy of unproven effectiveness,
Outcome 11 AOM within 4 to 8 weeks.
Review: Antibiotics for otitis media with effusion in children
Comparison: 1 Antibiotics versus placebo, no treatment or therapy of unproven effectiveness
Outcome: 11 AOM within 4 to 8 weeks
Study or subgroup Antibiotics Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Giebink 1990 5/20 9/19 13.6 % 0.53 [ 0.22, 1.29 ]
Healy 1984 2/100 5/100 7.4 % 0.40 [ 0.08, 2.01 ]
Mandel 1987 28/318 23/156 45.5 % 0.60 [ 0.36, 1.00 ]
Mandel 1991 25/235 10/75 22.3 % 0.80 [ 0.40, 1.58 ]
Schwartz 1982 3/30 8/33 11.2 % 0.41 [ 0.12, 1.41 ]
Total (95% CI) 703 383 100.0 % 0.60 [ 0.42, 0.85 ]
Total events: 63 (Antibiotics), 55 (Control)
Heterogeneity: Chi2 = 1.34, df = 4 (P = 0.85); I2 =0.0%
Test for overall effect: Z = 2.89 (P = 0.0039)
Test for subgroup differences: Not applicable
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Analysis 1.12. Comparison 1 Antibiotics versus placebo, no treatment or therapy of unproven effectiveness,
Outcome 12 AOM within 6 months.
Review: Antibiotics for otitis media with effusion in children
Comparison: 1 Antibiotics versus placebo, no treatment or therapy of unproven effectiveness
Outcome: 12 AOM within 6 months
Study or subgroup Antibiotics Control Risk Ratio Weight Risk Ratio
n/N n/N IV,Fixed,95% CI IV,Fixed,95% CI
Leach 2008 17/52 22/51 47.7 % 0.76 [ 0.46, 1.25 ]
Principi 1989 18/66 19/30 52.3 % 0.43 [ 0.27, 0.70 ]
Total (95% CI) 118 81 100.0 % 0.56 [ 0.40, 0.80 ]
Total events: 35 (Antibiotics), 41 (Control)
Heterogeneity: Chi2 = 2.55, df = 1 (P = 0.11); I2 =61%
Test for overall effect: Z = 3.24 (P = 0.0012)
Test for subgroup differences: Not applicable
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Analysis 2.1. Comparison 2 Sensitivity analysis - Antibiotics versus placebo, no treatment or therapy of
unproven effectiveness, Outcome 1 Complete resolution of OME at 2 to 3 months.
Review: Antibiotics for otitis media with effusion in children
Comparison: 2 Sensitivity analysis - Antibiotics versus placebo, no treatment or therapy of unproven effectiveness
Outcome: 1 Complete resolution of OME at 2 to 3 months
Study or subgroup Antibiotics Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ardehali 2008 12/30 3/30 5.8 % 4.00 [ 1.25, 12.75 ]
Chen 2013 33/36 23/37 43.6 % 1.47 [ 1.13, 1.93 ]
Marchisio 1998 19/52 11/59 19.8 % 1.96 [ 1.03, 3.72 ]
Safak 2001 51/60 12/30 30.8 % 2.13 [ 1.35, 3.34 ]
Total (95% CI) 178 156 100.0 % 1.92 [ 1.51, 2.44 ]
Total events: 115 (Antibiotics), 49 (Control)
Heterogeneity: Chi2 = 5.37, df = 3 (P = 0.15); I2 =44%
Test for overall effect: Z = 5.30 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 2.2. Comparison 2 Sensitivity analysis - Antibiotics versus placebo, no treatment or therapy of
unproven effectiveness, Outcome 2 Adverse effects.
Review: Antibiotics for otitis media with effusion in children
Comparison: 2 Sensitivity analysis - Antibiotics versus placebo, no treatment or therapy of unproven effectiveness
Outcome: 2 Adverse effects
Study or subgroup Antibiotics Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Hemlin 1997 6/61 0/20 4.7 % 4.40 [ 0.26, 74.88 ]
Marchisio 1998 0/52 0/59 Not estimable
van Balen 1996 29/74 15/71 95.3 % 1.85 [ 1.09, 3.16 ]
Total (95% CI) 187 150 100.0 % 1.97 [ 1.16, 3.35 ]
Total events: 35 (Antibiotics), 15 (Control)
Heterogeneity: Chi2 = 0.36, df = 1 (P = 0.55); I2 =0.0%
Test for overall effect: Z = 2.52 (P = 0.012)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours antibiotics Favours control
80Antibiotics for otitis media with effusion in children (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 2.3. Comparison 2 Sensitivity analysis - Antibiotics versus placebo, no treatment or therapy of
unproven effectiveness, Outcome 3 Complete resolution of OME at 2 to 4 weeks.
Review: Antibiotics for otitis media with effusion in children
Comparison: 2 Sensitivity analysis - Antibiotics versus placebo, no treatment or therapy of unproven effectiveness
Outcome: 3 Complete resolution of OME at 2 to 4 weeks
Study or subgroup Antibiotics Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Corwin 1986 33/66 22/65 15.4 % 1.48 [ 0.97, 2.24 ]
Daly 1991 5/21 2/21 6.3 % 2.50 [ 0.54, 11.48 ]
de Castro 1982 5/15 0/15 2.5 % 11.00 [ 0.66, 182.87 ]
Ernstson 1985 24/46 5/45 11.1 % 4.70 [ 1.96, 11.22 ]
Healy 1984 56/96 6/93 11.8 % 9.04 [ 4.09, 19.97 ]
Mandel 1991 69/235 20/75 15.3 % 1.10 [ 0.72, 1.68 ]
Marchisio 1998 15/52 7/59 11.6 % 2.43 [ 1.08, 5.50 ]
Safak 2001 52/60 14/30 15.6 % 1.86 [ 1.25, 2.76 ]
van Balen 1996 18/79 5/74 10.4 % 3.37 [ 1.32, 8.62 ]
Total (95% CI) 670 477 100.0 % 2.58 [ 1.60, 4.17 ]
Total events: 277 (Antibiotics), 81 (Control)
Heterogeneity: Tau2 = 0.34; Chi2 = 33.15, df = 8 (P = 0.00006); I2 =76%
Test for overall effect: Z = 3.88 (P = 0.00010)
Test for subgroup differences: Not applicable
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Analysis 2.4. Comparison 2 Sensitivity analysis - Antibiotics versus placebo, no treatment or therapy of
unproven effectiveness, Outcome 4 Complete resolution of OME at more than 6 months.
Review: Antibiotics for otitis media with effusion in children
Comparison: 2 Sensitivity analysis - Antibiotics versus placebo, no treatment or therapy of unproven effectiveness
Outcome: 4 Complete resolution of OME at more than 6 months
Study or subgroup Antibiotics Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Leach 2008 6/52 0/51 3.0 % 12.75 [ 0.74, 220.70 ]
Otten 1990 31/73 16/68 97.0 % 1.80 [ 1.09, 2.99 ]
Total (95% CI) 125 119 100.0 % 2.13 [ 1.30, 3.50 ]
Total events: 37 (Antibiotics), 16 (Control)
Heterogeneity: Chi2 = 1.93, df = 1 (P = 0.17); I2 =48%
Test for overall effect: Z = 2.98 (P = 0.0028)
Test for subgroup differences: Not applicable
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Analysis 2.5. Comparison 2 Sensitivity analysis - Antibiotics versus placebo, no treatment or therapy of
unproven effectiveness, Outcome 5 Complete resolution of OME at end of treatment (10 to 14 days).
Review: Antibiotics for otitis media with effusion in children
Comparison: 2 Sensitivity analysis - Antibiotics versus placebo, no treatment or therapy of unproven effectiveness
Outcome: 5 Complete resolution of OME at end of treatment (10 to 14 days)
Study or subgroup Antibiotics Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Duration of OME prior to study entry < 3 month
Daly 1991 5/21 2/21 10.8 % 2.50 [ 0.54, 11.48 ]
Mandel 1991 59/236 11/78 89.2 % 1.77 [ 0.98, 3.20 ]
Subtotal (95% CI) 257 99 100.0 % 1.85 [ 1.07, 3.21 ]
Total events: 64 (Antibiotics), 13 (Control)
Heterogeneity: Chi2 = 0.17, df = 1 (P = 0.68); I2 =0.0%
Test for overall effect: Z = 2.20 (P = 0.028)
2 Duration of OME prior to study entry≥ 3 months
Ernstson 1985 24/46 5/45 49.5 % 4.70 [ 1.96, 11.22 ]
van Balen 1996 18/79 5/74 50.5 % 3.37 [ 1.32, 8.62 ]
Subtotal (95% CI) 125 119 100.0 % 4.03 [ 2.13, 7.61 ]
Total events: 42 (Antibiotics), 10 (Control)
Heterogeneity: Chi2 = 0.26, df = 1 (P = 0.61); I2 =0.0%
Test for overall effect: Z = 4.29 (P = 0.000018)
Test for subgroup differences: Chi2 = 3.28, df = 1 (P = 0.07), I2 =70%
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Analysis 2.6. Comparison 2 Sensitivity analysis - Antibiotics versus placebo, no treatment or therapy of
unproven effectiveness, Outcome 6 Complete resolution of OME at end of treatment (4 weeks).
Review: Antibiotics for otitis media with effusion in children
Comparison: 2 Sensitivity analysis - Antibiotics versus placebo, no treatment or therapy of unproven effectiveness
Outcome: 6 Complete resolution of OME at end of treatment (4 weeks)
Study or subgroup Antibiotics Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
de Castro 1982 5/15 0/15 7.6 % 11.00 [ 0.66, 182.87 ]
Healy 1984 56/96 6/93 92.4 % 9.04 [ 4.09, 19.97 ]
Total (95% CI) 111 108 100.0 % 9.19 [ 4.29, 19.70 ]
Total events: 61 (Antibiotics), 6 (Control)
Heterogeneity: Chi2 = 0.02, df = 1 (P = 0.90); I2 =0.0%
Test for overall effect: Z = 5.70 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 2.7. Comparison 2 Sensitivity analysis - Antibiotics versus placebo, no treatment or therapy of
unproven effectiveness, Outcome 7 AOM within 4 to 8 weeks.
Review: Antibiotics for otitis media with effusion in children
Comparison: 2 Sensitivity analysis - Antibiotics versus placebo, no treatment or therapy of unproven effectiveness
Outcome: 7 AOM within 4 to 8 weeks
Study or subgroup Antibiotics Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Healy 1984 2/100 5/100 24.8 % 0.40 [ 0.08, 2.01 ]
Mandel 1991 25/235 10/75 75.2 % 0.80 [ 0.40, 1.58 ]
Total (95% CI) 335 175 100.0 % 0.70 [ 0.37, 1.31 ]
Total events: 27 (Antibiotics), 15 (Control)
Heterogeneity: Chi2 = 0.60, df = 1 (P = 0.44); I2 =0.0%
Test for overall effect: Z = 1.12 (P = 0.26)
Test for subgroup differences: Not applicable
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A D D I T I O N A L T A B L E S
Table 1. Details of type and duration of antibiotic and control treatment used in the included trials
Type of antibiotic N* Treatment duration N
Amoxicillin 6 10 to 14 days 15
TMP-SMX 6 4 weeks 6
Amoxicillin/clavulanic acid 5 3 months 2
Cefaclor 3 6 months 2
Erythromycin-sulfisoxazole 2 - -
Erythromycin 1 - -
Sulfisoxazole 1 - -
Azithromycin 1 - -
Cefixime 1 - -
Ceftibuten 1 - -
Clarithromycin 1 - -
* Numbers do not add up to 25 because some trials assessed the effect of multiple antibiotics.
TMP-SMX: trimethoprim-sulfamethoxazole
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A P P E N D I C E S
Appendix 1. Search strategies
CENTRAL PubMed EMBASE (Ovid)
#1 MeSH descriptor Otitis Media with Ef-
fusion explode all trees
#2 MeSH descriptor Ear, Middle explode
all trees with qualifier: SE
#3 glue NEXT ear OR otitis NEXT me-
dia NEAR effusion* OR middle NEXT
ear NEAR effusion* OR nonsuppurative
NEXT otitis OR non NEXT suppurative
NEXT otitis
#4 tympanitis OR serous NEXT otitis OR
secretory NEXT otitis OR otitis NEXT
serosa
#5 mucoid NEAR otitis OR mucous
NEAR otitis OR seromuco* NEAR otitis
OR sero NEXT muco* NEAR otitis
#6 mucoid NEAR middle NEXT ear OR
mucousNEARmiddleNEXTearOR sero-
muc* NEAR middle NEXT ear
#7 adhesive NEAR otitis OR exudative
NEAR otitis
#8 #1 OR #2 OR #3 OR #4 OR #5 OR #
6 OR #7
#9 MeSH descriptor Anti-Bacterial Agents
explode all trees
#10 MeSH descriptor Antibiotic Prophy-
laxis explode all trees
#11 MeSH descriptor Lactams explode all
trees
#12 MeSH descriptor Quinolones explode
all trees
#13 MeSH descriptor Macrolides explode
all trees
#14 antibiot* OR (anti NEXT biot*) OR
antimicrobial* OR (anti NEXT micro-
bial*) OR bacteriocid* OR antibacterial*
OR (anti NEXT bacterial*)
#15 penicillin* OR amoxicillin OR ampi-
cillin OR clavulanic acid OR amoxiclav
OR augmentinOR ticarcillinOR timentin
OR flucloxacillin OR fluampicil OR mag-
napen OR piperacillin OR tazocin
#16 cephalosporin* OR cefaclor OR dista-
clor OR cefadroxil OR baxan OR cefalexin
(“Otitis Media with Effusion”[Mesh])
OR (“Ear, Middle/secretion”[Mesh]) OR
(“glue ear”[tiab] OR (otitis[tiab] ANDme-
dia[tiab] AND effusion[tiab])) OR ((mid-
dle[ti] ANDear[ti] ANDeffusion*[ti])OR
“nonsuppurative otitis”[ti] OR “non sup-
purative otitis”[ti] OR tympanitis[ti] OR
“serous otitis”[ti] OR “secretory otitis”[ti]
OR “otitis serosa”[ti] OR (mucoid[ti]
AND otitis[ti]) OR (mucous[ti] AND oti-
tis[ti]) OR (seromuco*[ti] AND otitis[ti])
OR (sero[ti] AND muco*[ti] AND oti-
tis[ti]) OR (mucoid[ti] AND middle[ti]
AND ear[ti]) OR (mucous[ti] AND mid-
dle[ti] AND ear[ti]) OR (seromuc*[ti]
AND middle[ti] AND ear[ti]) OR (adhe-
sive[ti] AND otitis[ti]) OR (exudative[ti]
AND otitis[ti]))) AND (macrolide*[tiab]
OR erythromycin[tiab] OR erymax[tiab]
OR erythrocin[tiab] OR erythroped[tiab]
OR azithro-
mycin[tiab] OR zithromax[tiab] OR clar-
ithromycin[tiab] OR klaricid[tiab] OR
telithromycin[tiab] OR sulfisoxazole[tiab]
OR ketek[tiab] OR trimoxazole[tiab] OR
septrin[tiab] OR trimethoprim[tiab] OR
monotrim[tiab] OR trimopan[tiab] OR
metronidazole[tiab] OR flagyl[tiab] OR
metrolyl[tiab] OR quinolone*[tiab] OR
ciprofloxacin[tiab] OR ciproxin[tiab] OR
phenoxymethylpenicillin[tiab] OR sul-
famethoxazole[tiab]ORoxacillin[tiab]OR
cephalothin[tiab] OR sulbactam[tiab] OR
ofloxacin[tiab] OR clindamycin[tiab] OR
gentamycin[tiab] OR vancomycin)
1 exp *secretory otitis media/
2 (glue and ear).tw.
3 (otitis and media and effusion).tw.
4 ((middle and ear and effusion*) or (non-
suppurative adj otitis) or (non adj suppu-
rative adj otitis) or tympanitis or (serous
adj otitis) or (secretory adj otitis) or (otitis
adj serosa) or (mucoid and otitis) or (mu-
cous and otitis) or (seromuco* and otitis)
or (sero and muco* and otitis) or (mucoid
and middle and ear) or (mucous and mid-
dle and ear) or (seromuc* and middle and
ear) or (adhesive and otitis) or (exudative
and otitis)).ti.
5 1 or 2 or 3 or 4
6 exp antibiotic agent/
7 exp antibiotic agent/
8 (antibiot* or (anti and biot*) or antimi-
crobial* or (anti and microbial*) or bacte-
riocid* or antibacterial* or (anti and bacte-
rial*) or penicillin* or amoxicillin or ampi-
cillin or clavulanic or amoxiclav or aug-
mentin or ticarcillin or timentin or flu-
cloxacillin or fluampicil or magnapen or
piperacillin or tazocin).tw.
9 (cephalosporin* or cefaclor or distaclor or
cefadroxil or baxan or cefalexin or ceporex
or keflex or cefamandole or kefadol or cefa-
zolin or kefzol or cefixime or suprax or cefo-
taxime or claforan or cefoxitin or mefoxin
or cefpirome or cefrom or cefpodoxime or
orelox or cefprozil or cefzil or cefradine or
velosel or ceftazidime or fortum or kefadim
or ceftriaxone or rocephin or cefuroxime
or zinacef or zinnat or cefonicid or aztre-
onam or azactam or imipenem or cilastatin
or primaxin or meropenem or meronem or
tetracycline* or deteclo or demecleocyclin
or ledermycin or doxycycline or vibramycin
or minocycline or minocine or oxytetracy-
cline or terramycin).tw.
10 (macrolide* or erythromycin or ery-
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(Continued)
OR ceporex OR keflex OR cefamandole
OR kefadol OR cefazolin OR kefzol OR
cefixime OR suprax OR cefotaxime OR
claforanORcefoxitinORmefoxinOR cef-
pirome OR cefrom OR cefpodoxime OR
oreloxORcefprozilORcefzilORcefradine
ORveloselORceftazidimeOR fortumOR
kefadim OR ceftriaxone OR rocephin OR
cefuroxime OR zinacef OR zinnat OR ce-
fonicid OR aztreonam OR azactam OR
imipenem OR cilastatin OR primaxin OR
meropenem or meronem or tetracycline*
or deteclo or demecleocyclin or ledermycin
or doxycycline or vibramycin or minocy-
cline or minocine or oxytetracycline or ter-
ramycin
#17 macrolide* OR erythromycin OR
erymax OR erythrocin OR erythroped
OR azithromycin OR zithromax OR clar-
ithromycin OR klaricid OR telithromycin
OR sulfisoxazole OR ketek OR trimoxa-
zole OR septrin
#18 trimethoprim OR monotrim OR tri-
mopan OR metronidazole OR flagyl OR
metrolyl OR quinolone* OR ciprofloxacin
OR ciproxin or phenoxymethylpenicillin
OR sulfamethoxazole OR oxacillin OR
cephalothin OR sulbactam OR ofloxacin
OR clindamycin OR gentamycin OR van-
comycin
#19 #9 OR #10 OR #11 OR #12 OR #13
OR #14 OR #15 OR #16 OR #17 OR #
18
#20 #8 AND #19
max or erythrocin or erythroped or azithro-
mycin or zithromax or clarithromycin or
klaricid or telithromycin or sulfisoxazole
or ketek or trimoxazole or septrin or
trimethoprim or monotrim or trimopan
or metronidazole or flagyl or metrolyl or
quinolone* or ciprofloxacin or ciproxin or
phenoxymethylpenicillin or sulfamethoxa-
zole or oxacillin or cephalothin or sulbac-
tam or ofloxacin or clindamycin or gen-
tamycin or vancomycin or sulfisoxazole).
tw.
11 7 or 8 or 9 or 10
12 5 and 11
CINAHL (EBSCO) Web of Science (Web of Knowledge) ICTRP
#1 TS=((glue adj ear) OR (otitis ANDme-
dia AND effusion))
#2 TI=((middle AND ear AND effusion*)
OR (nonsuppurative adj otitis) OR (non
adj suppurative adj otitis) OR tympanitis
OR (serous adj otitis) OR (secretory adj
otitis) OR (otitis adj serosa) OR (mucoid
AND otitis) OR (mucous AND otitis) OR
(seromuco* AND otitis) OR (sero AND
muco* AND otitis) OR (mucoid AND
middle AND ear) OR (mucous ANDmid-
dle AND ear) OR (seromuc* ANDmiddle
#1 TS=((glue adj ear) OR (otitis adj media
adj effusion))
#2 TI=((middle AND ear AND effusion*)
OR (nonsuppurative adj otitis) OR (non
adj suppurative adj otitis) OR tympanitis
OR (serous adj otitis) OR (secretory adj
otitis) OR (otitis adj serosa) OR (mucoid
AND otitis) OR (mucous AND otitis) OR
(seromuco* AND otitis) OR (sero AND
muco* AND otitis) OR (mucoid AND
middle AND ear)OR (mucous ANDmid-
dle AND ear) OR (seromuc* ANDmiddle
otitis AND media AND effusion OR glue
AND ear ORmiddle AND ear AND effu-
sion OR otitis AND secretory
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(Continued)
AND ear) OR (adhesive AND otitis) OR
(exudative AND otitis))
#3 TS=(antibiot* OR (anti AND biot*)
OR antimicrobial* OR (anti AND mi-
crobial*) OR bacteriocid* OR antibac-
terial* OR (anti AND bacterial*) OR
penicillin* OR amoxicillin OR ampicillin
OR clavulanic OR amoxiclav OR aug-
mentinOR ticarcillinOR timentinORflu-
cloxacillin OR fluampicil OR magnapen
OR piperacillin OR tazocin)
#4 TS=(cephalosporin* OR cefaclor OR
distaclor OR cefadroxil OR baxan OR
cefalexin OR ceporex OR keflex OR
cefamandole OR kefadol OR cefazolin OR
kefzol OR cefixime OR suprax OR ce-
fotaxime OR claforan OR cefoxitin OR
mefoxin OR cefpirome OR cefrom)
#5 TS=(cefpodoxime OR orelox OR cef-
prozil OR cefzil OR cefradine OR velosel
OR ceftazidime OR fortum OR kefadim
OR ceftriaxone OR rocephin OR ce-
furoxime OR zinacef OR zinnat OR ce-
fonicid OR aztreonam OR azactam OR
imipenem OR cilastatin OR primaxin OR
meropenem or meronem or tetracycline*
or deteclo or demecleocyclin or ledermycin
or doxycycline or vibramycin or minocy-
cline or minocine or oxytetracycline or ter-
ramycin)
#6 TS=(macrolide* OR erythromycin OR
erymax OR erythrocin OR erythroped
OR azithromycin OR zithromax OR clar-
ithromycin OR klaricid OR telithromycin
OR sulfisoxazole OR ketek OR trimox-
azole OR septrin OR trimethoprim OR
monotrim OR trimopan OR metronida-
zoleORflagylORmetrolylORquinolone*
OR ciprofloxacin OR ciproxin or phe-
noxymethylpenicillin OR sulfamethoxa-
zole OR oxacillin OR cephalothin OR sul-
bactamOR ofloxacin OR clindamycin OR
gentamycin OR vancomycin OR sulfisox-
azole)
#7 #2 OR #1
#8 #3 OR #4 OR #5 OR #6
#9 #7 AND #8
AND ear) OR (adhesive AND otitis) OR
(exudative AND otitis))
#3 #1 OR #2
#4 TS=(antibiot* OR (anti AND biot*)
OR antimicrobial* OR (anti AND mi-
crobial*) OR bacteriocid* OR antibac-
terial* OR (anti AND bacterial*) OR
penicillin* OR amoxicillin OR ampicillin
OR clavulanic OR amoxiclav OR aug-
mentinOR ticarcillinOR timentinORflu-
cloxacillin OR fluampicil OR magnapen
OR piperacillin OR tazocin)
#5 TS=(cephalosporin* OR cefaclor OR
distaclor OR cefadroxil OR baxan OR
cefalexin OR ceporex OR keflex OR
cefamandole OR kefadol OR cefazolin OR
kefzol OR cefixime OR suprax OR ce-
fotaxime OR claforan OR cefoxitin OR
mefoxin OR cefpirome OR cefrom)
#6 TS=(cefpodoxime OR orelox OR cef-
prozil OR cefzil OR cefradine OR velosel
OR ceftazidime OR fortum OR kefadim
OR ceftriaxone OR rocephin OR ce-
furoxime OR zinacef OR zinnat OR ce-
fonicid OR aztreonam OR azactam OR
imipenem OR cilastatin OR primaxin OR
meropenem or meronem or tetracycline*
or deteclo or demecleocyclin or ledermycin
or doxycycline or vibramycin or minocy-
cline or minocine or oxytetracycline or ter-
ramycin)
#7 TS=(macrolide* OR erythromycin OR
erymax OR erythrocin OR erythroped
OR azithromycin OR zithromax OR clar-
ithromycin OR klaricid OR telithromycin
OR sulfisoxazole OR ketek OR trimox-
azole OR septrin OR trimethoprim OR
monotrim OR trimopan OR metronida-
zoleORflagylORmetrolylORquinolone*
OR ciprofloxacin OR ciproxin or phe-
noxymethylpenicillin OR sulfamethoxa-
zole OR oxacillin OR cephalothin OR sul-
bactamOR ofloxacin OR clindamycin OR
gentamycin OR vancomycin OR sulfisox-
azole)
#8 #7 OR #6 OR #5 OR #4
#9 #8 OR #3
#10 #8 AND #3
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WH A T ’ S N E W
Last assessed as up-to-date: 14 April 2016.
Date Event Description
14 April 2016 New citation required but conclusions have not changed In general, the results and conclusions regarding the ben-
efits and harms of oral antibiotics for otitis media with
effusion in children remain unchanged
14 April 2016 New search has been performed We updated the search on 14 April 2016.
In the original version of our review 23 studies were in-
cluded (van Zon 2012). In this 2016 update, we included
one new study and excluded one study that was previ-
ously included on the basis that this was not a randomised
controlled trial. We also included two trials that were pre-
viously excluded on the basis that they did not report
on any outcomes of interest (according to new Cochrane
standards), but these trials provided no relevant data for
this review. This left 23 trials (3258 children) that re-
ported on at least one of our outcomes of interest.
We did not identify any ongoing trials.
One new review author (Roderick Venekamp) joined the
team to update this review
C O N T R I B U T I O N S O F A U T H O R S
Original version of the review (van Zon 2012):
Alice van Zon (AvZ): protocol development, selection of eligible studies, quality assessment of trials, data extraction, analyses and
interpretation of data, and development of the final review.
Geert J van der Heijden (GJvdH): protocol development, analyses and interpretation of data, revision of the review and approval of
the final content.
Thijs MA van Dongen (TMAvD): selection of eligible studies, quality assessment of trials and data extraction.
Martin J Burton (MJB): interpretation of data, revision of the review and approval of the final content.
Anne GM Schilder (AGMS): initiation of the review, protocol development, interpretation of data, revision of the review and approval
of the final content.
2016 update of the review:
Roderick Paul Venekamp (RPV): selection of eligible studies, quality assessment of trials, data extraction, analyses and interpretation
of data, and writing of the 2016 updated review
TMAvD: selection of eligible studies, quality assessment of trials, data extraction, interpretation of data, revision of the review and
approval of the final content.
GJvdH, AvZ, MJB and AGMS: interpretation of data, revision of the review and approval of the final content.
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D E C L A R A T I O N S O F I N T E R E S T
AGMS has received an honorarium from GlaxoSmithKline for participating in educational activities and workshops related to pneu-
mococcal vaccination and otitis media. She has received funds from GlaxoSmithKline for research on microbial pathogens in acute
tympanostomy tube otorrhoea.
AGMS and MJB are Co-ordinating Editors of Cochrane ENT, but had no role in the editorial process for this review.
RPV is an Editor for the Cochrane Acute Respiratory Infections Group and Cochrane ENT, but had no role in the editorial process
for this review.
TMAvD, AGMS and RPV were involved in research on microbial pathogens in acute tympanostomy tube otorrhoea, partly funded
by GlaxoSmithKline.
S O U R C E S O F S U P P O R T
Internal sources
• No sources of support supplied
External sources
• National Institute for Health Research, UK.
Cochrane Review Incentive Award 2011 (original publication of review)
• National Institute for Health Research, UK.
Infrastructure funding for Cochrane ENT
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
Original version of the review (van Zon 2012):
The following changes were made in the final version of the review:
Two co-authors, not mentioned in the protocol version, contributed to the review (TMAvD and MJB).
Types of participants
Although we planned to include only studies in which the clinical diagnosis of OME was made by a combination of otoscopy,
tympanometry and/or audiometry, we decided to include studies using tympanometry alone or in combination with otoscopy.
Data synthesis
We planned to perform stratified analyses regarding the outcome complete resolution of OME.Due to thin data and large heterogeneity
amongst the included studies, we could not present the results of these analyses.
2016 update of the review:
• A new review author (RPV) joined the team to update this review.
• In the original 2012 review, we included the following as a secondary outcome measure:
Partial or complete resolution of OME (partial or complete treatment success) at all possible time points defined as resolution of
OME in the affected ear in children with unilateral OME at randomisation and resolution of OME in one or both ears in children
with bilateral OME at randomisation; in either case, the diagnosis having been made by tympanometry alone or in combination with
otoscopy.
We felt that partial improvement in the form of resolution of OME in one ear in a child with bilateral OME might be a clinical
meaningful improvement. However, we found that this analysis did not contribute to the overall clinical implications of this review
90Antibiotics for otitis media with effusion in children (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
and made readability and interpretation more difficult. We therefore removed this outcome measure and the subsequent analyses based
upon it.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Anti-Bacterial Agents [∗therapeutic use]; Bacterial Infections [∗drug therapy]; Hearing Loss [drug therapy; prevention & control];
Otitis Media with Effusion [∗drug therapy; microbiology]; Randomized Controlled Trials as Topic; Time Factors; Treatment Outcome
MeSH check words
Adolescent; Child; Child, Preschool; Humans; Infant
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